

Supplementary Information

Synthesis of spirosuccinimides via annulative cyclization between *N*-aryl indazolols and maleimides under rhodium(III) catalysis

Ju Young Kang,^{a,‡} Won An,^{a,‡} Suho Kim,^a Na Yeon Kwon,^a Taejoo Jeong,^a Prithwish Ghosh,^a Hyung Sik Kim,^a Neeraj Kumar Mishra^{a,*} and In Su Kim^{a,*}

^a School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea

* Corresponding authors. E-mails: neerajchemistry@gmail.com (N.K.M.), insukim@skku.edu (I.S.K.)

‡ These authors equally contributed.

List of the Contents


| | |
|---|---------|
| General methods ----- | S3 |
| General scheme, procedures, and characterization data for the synthesis of <i>N</i> -phenyl indazol-3-ol (1n) ----- | S4–S5 |
| General procedure and characterization data of celecoxib maleimide 2q ----- | S6–S8 |
| General procedure and characterization data of estrone maleimide 2r ----- | S9–S10 |
| General procedure and characterization data of metronidazole maleimide 2s ----- | S11 |
| General procedure for the spiroannulation of <i>N</i> -aryl indazol-3-ols with maleimides and maleates (3aa, 3a–3n, 4b–4m, and 4o–4t) ----- | S12 |
| Characterization data for all products (3aa, 3a–3n, 4b–4m, and 4o–4t) ----- | S13–S32 |
| General procedure and ¹ H NMR copy for deuterium-labeling experiment ----- | S33–S34 |
| General procedure and characterization data for the synthesis of rhodacycle-1a ----- | S35 |
| Experimental procedure for the reaction of 1a and 2a using rhodacycle-1a ----- | S36 |

| | |
|---|------------------|
| Experimental procedure for the reaction of 1a and 2a using [RhCp*(OAc)₂] ----- | S37 |
| General procedure for the spiroannulation of rhodacycle-1a with maleimide for the formation of 3a ----- | S38 |
| General procedure and characterization data for the reaction of 1-phenyl-1<i>H</i>-indazol-3-ol (1a) with 1-methyl-1,5-dihydro-2<i>H</i>-pyrrol-2-one (5a) ----- | S39 |
| General procedure for the gram scale experiment of 3a ----- | S40 |
| X-ray crystallographic data of 1-phenyl-1<i>H</i>-indazol-3-ol (1a) (CCDC 2096892) ---- | S41–S50 |
| X-ray crystallographic data of rhodacycle-1a (CCDC 2095228) ----- | S51–S65 |
| Computational studies for the stability of tautomers ----- | S66 |
| References----- | S67 |
| ¹H NMR and ¹³C NMR spectra of all compounds ----- | S68–S107 |
| ¹⁹F NMR spectra of F-containing compounds ----- | S108–S111 |

General methods

Commercially available reagents were used without additional purification, unless otherwise stated. *N*-Aryl indazol-3-ols **1a–1m** were prepared according to the reported literatures.¹ Maleimides **2b–2h**, **2k**, and **2t** were purchased from TCI. Maleates **2o** and **2p** were purchased from TCI. Maleimides **2i**, **2j**, **2l**, and **2n** were prepared according to the reported literatures.² 1-Methyl-1,5-dihydro-2*H*-pyrrol-2-one (**5a**) as an α,β -unsaturated γ -lactam was prepared according to the reported literature.³ All the reactions were performed in an oil bath by using IKA universal hot plate magnetic stirrer. Sealed tubes ($13 \times 100 \text{ mm}^2$) were purchased from Fischer Scientific and dried in oven for overnight and cooled at room temperature prior to use. Thin layer chromatography was carried out using plates coated with Kieselgel 60F₂₅₄ (Merck). For flash column chromatography, E. Merck Kieselgel 60 (230–400 mesh) was used. Nuclear magnetic resonance spectra (¹H, ¹³C, and ¹⁹F NMR) were recorded on a Bruker Unity 300, 400, 500, and 700 MHz spectrometers in CDCl₃, CD₃COCD₃, and DMSO-d₆ solution and chemical shifts are reported as parts per million (ppm). Resonance patterns are reported with the notations s (singlet), br (broad), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets), doublet of doublet of triplets (ddt), doublet of quartets (dq), td (triplet of doublets), and m (multiplet). In addition, the notation br is used to indicate a broad signal. Coupling constants (*J*) are reported in hertz (Hz). IR spectra were recorded on a Varian 2000 Infrared spectrophotometer and are reported as cm⁻¹. High-resolution mass spectra (HRMS) were recorded on a JEOL JMS-600 spectrometer.

General scheme, procedures, and characterization data for the synthesis of *N*-phenyl indazol-3-ol (**1n**)



Experimental procedure for the synthesis of **1nc**


To an oven-dried round bottom flask charged with 2-chloro-5-nitrobenzoic acid (2.0 g, 10.0 mmol, 100 mol %) in DMF (20 mL) were added EDC·HCl (2.1 g, 11.0 mmol, 110 mol %), HOBr·H₂O (1.49 g, 11.0 mmol, 110 mol %), 4-(dimethylamino)pyridine (DMAP, 61.1 mg, 0.5 mmol, 5 mol %), and phenylhydrazine (1.0 mL, 10.0 mmol, 100 mol %) at 0 °C under N₂ atmosphere. The reaction mixture was allowed to stir for 24 h at room temperature. The reaction mixture was diluted with EtOAc (50 mL) and poured into saturated NH₄Cl solution. Extractive workup with EtOAc (2 x 50 mL). The combined organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 3:1 to 1:1) to afford 1.87 g of **1nc** as a white solid in 64 % yield.

Experimental procedure and characterization data for the synthesis of **1n**

To an oven-dried round bottom flask charged with **1nc** (1.31 g, 4.5 mmol, 100 mol %), CuI (5.1 mg, 0.027 mmol, 0.6 mol %), and L-proline (103.6 mg, 0.9 mmol, 20 mol %) were added K₂CO₃ (1.24 g, 9.0 mmol, 200 mol %) and DMSO (15 mL) at room temperature under N₂ atmosphere. The reaction mixture was allowed to stir for 24 h at 90 °C. The reaction mixture was cooled to room temperature, treated with saturated NaHCO₃ solution (100 mL), and extracted with EtOAc (8 x 30 mL). The combined organic layer was washed with H₂O (3 x 50 mL) and

brine (50 mL), dried over MgSO₄, filtered, and concentrated under reduced pressure. The obtained residue was recrystallized with diethyl ether (10 mL) to afford 0.6 g of **1n** as a yellow solid in 52% yield.

5-Nitro-1-phenyl-1,2-dihydro-3*H*-indazol-3-one (1n**)**




0.6 g (52%); yellow solid; mp = 294.7–297.5 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 11.9 (s, 1H), 8.74 (d, *J* = 2.0 Hz, 1H), 8.23 (dd, *J* = 9.6, 2.4 Hz, 1H), 7.86 (d, *J* = 9.2 Hz, 1H), 7.71 (d, *J* = 7.6 Hz, 2H), 7.57 (t, *J* = 7.6 Hz, 2H), 7.38 (t, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ 157.9, 140.9, 140.6, 138.9, 129.7, 126.5, 123.0, 121.7, 118.5, 114.1, 111.1; IR (KBr) ν 3056, 2987, 1668, 1602, 1566, 1516, 1342, 1281, 1228, 1140 cm⁻¹; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₁₃H₉N₃O₃ 255.0644; Found 255.0641.

General procedure and characterization data of celecoxib maleimide **2q**


Experimental procedure for the synthesis of celecoxib derivative **2qb**

Aldehydic celecoxib **2qa**, 4-(5-(4-formylphenyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)benzenesulfonamide, was synthesized by using the commercially available celecoxib, according to previously reported procedure.⁴



To an oven-dried round bottom flask charged with aldehydic celecoxib **2qa** (520.0 mg, 1.3 mmol, 1.0 equiv.) was added EtOH (6.6 mL, 0.2 M). To the above mixture was added NaBH₄ (99.5 mg, 2.6 mmol, 2.0 equiv.) in one portion. The reaction mixture was allowed to stir for 45 min at 0 °C. The reaction mixture was dropwise quenched by *s*-NH₄Cl solution (2 mL), and filtered through Celite pad. The filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 3:1 to 1:2) to afford 0.42 g of celecoxib derivative **2qb** as a white sticky solid in 81% yield.

4-(5-(4-(Hydroxymethyl)phenyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl)benzenesulfonamide (**2qb**)



0.42 g (81%); eluent (*n*-hexanes/EtOAc = 3:1 to 1:2); white sticky solid; ¹H NMR (500 MHz, CD₃COCD₃) δ 7.95 (dt, *J* = 8.5, 2.5 Hz, 2H), 7.56 (dt, *J* = 8.5, 2.5 Hz, 2H), 7.41 (d, *J* = 8.5 Hz, 2H), 7.32 (d, *J* = 8.5 Hz, 2H), 7.01 (s, 1H), 6.74 (s, 2H), 4.67 (d, *J* = 5.5 Hz, 2H), 4.34 (t,


$J = 5.5$ Hz, 1H); ^{13}C NMR (125 MHz, CD_3COCD_3) δ 146.4, 145.0, 144.9, 143.9 (q, $J_{\text{C}-\text{F}} = 37.9$ Hz), 142.9, 129.8, 128.1, 128.0, 127.6, 126.7, 124.6 (q, $J_{\text{C}-\text{F}} = 265.1$ Hz), 106.9 (q, $J_{\text{C}-\text{F}} = 2.5$ Hz), 64.1; ^{19}F NMR (376 MHz, CDCl_3) δ -62.5 (s); IR (KBr) ν 3270, 1498, 1471, 1407, 1338, 1272, 1236, 1159, 1132, 1097, 1024, 975, 942 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{17}\text{H}_{14}\text{F}_3\text{N}_3\text{O}_3\text{S}$ 397.0708; Found 397.0703.

Experimental procedure for the synthesis of celecoxib maleimide **2q** from **2qb**

To an oven-dried round bottom flask charged with commercially available 3-maleimidopropionic acid (209.0 mg, 1.24 mmol, 1.2 equiv.) and SOCl_2 (0.45 mL, 6.2 mmol, 6 equiv.) under N_2 atmosphere. The reaction mixture was allowed to stir for 30 min at 80 °C. The reaction mixture was cooled to room temperature and concentrated in vacuo to obtain the 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoyl chloride.

Next, to an oven-dried round bottom flask charged with **2qb** (0.41 g, 1.03 mmol, 1.0 equiv.) and CH_2Cl_2 (5 mL) was added Et_3N (0.27 mL, 1.9 mmol, 1.8 equiv.). The reaction mixture was allowed to stir for 15 min at 0 °C. Then, 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoyl chloride and CH_2Cl_2 (3 mL) were added to the above reaction mixture, and the resulting mixture was allowed to stir at room temperature for 4 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 3:1 to 1:1) to afford 140.2 mg of celecoxib maleimide **2q** as a white sticky solid in 25% yield.

4-(1-(4-Sulfamoylphenyl)-3-(trifluoromethyl)-1*H*-pyrazol-5-yl)benzyl 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoate (**2q**)




0.14 g (25%); eluent (*n*-hexanes/EtOAc = 3:1 to 1:1); white sticky solid; ^1H NMR (400 MHz, CDCl_3) δ 7.93–7.90 (m, 2H), 7.48–7.44 (m, 2H), 7.35 (d, $J = 8.4$ Hz, 2H), 7.22 (d, $J = 8.4$

Hz, 2H), 6.78 (s, 1H), 6.70 (s, 2H), 5.12 (s, 2H), 5.10 (s, 2H), 3.84 (t, $J = 7.2$ Hz, 2H), 2.71 (t, $J = 7.2$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.6, 170.5, 144.7, 144.3 (q, $J_{\text{C-F}} = 37.3$ Hz), 142.4, 141.8, 137.3, 134.4, 129.2, 128.9, 128.7, 127.7, 125.7, 121.1 (q, $J_{\text{C-F}} = 270.4$ Hz), 106.8 (q, $J_{\text{C-F}} = 2.5$ Hz), 65.9, 33.7, 33.0; ^{19}F NMR (376 MHz, CDCl_3) δ -62.4 (s); IR (KBr) ν 3268, 3102, 2923, 1704, 1446, 1407, 1373, 1342, 1267, 12324, 1160, 1130, 1097, 973, 898, 827 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{24}\text{H}_{19}\text{F}_3\text{N}_4\text{O}_6\text{S}$ 548.0977; Found 548.0977.

General procedure and characterization data of estrone maleimide **2r**

To an oven-dried round bottom flask charged with commercially available 3-maleimidopropionic acid (75.0 mg, 0.44 mmol, 1.2 equiv.) and SOCl_2 (0.2 mL, 2.64 mmol, 6 equiv.) under N_2 atmosphere. The reaction mixture was allowed to stir for 30 min at 80 °C. The reaction mixture was cooled to room temperature and concentrated in vacuo to obtain the 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoyl chloride. Next, to an oven-dried round bottom flask charged with commercially available estrone (97.2 mg, 0.36 mmol, 1.0 equiv.) and CH_2Cl_2 (1 mL), cooled in an ice bath and was added Et_3N (0.1 mL, 0.65 mmol, 1.8 equiv.). The reaction mixture was allowed to stir for 15 min at 0 °C. Then, 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoyl chloride and CH_2Cl_2 (1 mL) were added to the above reaction mixture, and the resulting mixture was allowed to stir at room temperature for 4 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc = 5:1 to 2:1) to afford 97.0 mg of estrone maleimide **2r** as a white solid in 43% yield.

(8*R*,9*S*,13*S*,14*S*)-13-Methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phenanthren-2-yl 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoate (**2r**)



97.0 mg (43%); eluent (*n*-hexanes/EtOAc = 5:1 to 2:1); white solid; mp = 153.8–156.6 °C; ¹H NMR (400 MHz, CDCl_3) δ 7.28 (d, *J* = 8.8 Hz, 1H), 6.86 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.81 (d, *J* = 2.4 Hz, 1H), 6.72 (s, 2H), 3.95 (t, *J* = 6.8 Hz, 2H), 2.92–2.86 (m, 4H), 2.50 (dd, *J* = 19.2, 8.8 Hz, 1H), 2.42–2.37 (m, 1H), 2.31–2.24 (m, 1H), 2.19–1.94 (m, 4H), 1.68–1.39 (m, 6H), 0.90 (s, 3H); ¹³C NMR (100 MHz, CDCl_3) δ 170.4, 169.6, 148.4, 138.2, 137.7, 134.4, 126.6, 121.6, 118.8, 50.6, 48.1, 44.3, 38.1, 36.0, 33.7, 33.2, 31.7, 29.5, 26.5, 25.9, 21.7, 13.9; IR (KBr) ν 2931,

2861, 1733, 1680, 1492, 1444, 1407, 1375, 1315, 1245, 1220, 1159, 1058, 1008, 910, 827 cm⁻¹;
HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₂₅H₂₇NO₅ 421.1889; Found 421.1886.


General procedure and characterization data of metronidazole maleimide **2s**

To an oven-dried round bottom flask charged with commercially available 3-maleimidopropionic acid (209.7 mg, 1.24 mmol, 1.0 equiv.) and SOCl_2 (0.54 mL, 7.44 mmol, 6 equiv.) under N_2 atmosphere. The reaction mixture was allowed to stir for 30 min at 80 °C. The reaction mixture was cooled to room temperature and concentrated in vacuo to obtain the 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoyl chloride. Next, to an oven-dried round bottom flask charged with commercially available metronidazole (318.3 mg, 1.86 mmol, 1.5 equiv.) and CH_2Cl_2 (5 mL), cooled in an ice bath and was added Et_3N (0.52 mL, 3.72 mmol, 3.0 equiv.). The reaction mixture was allowed to stir for 15 min at 0 °C. Then, 3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoyl chloride and CH_2Cl_2 (4 mL) were added to the above reaction mixture, and the resulting mixture was allowed to stir at room temperature for 3 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 2:1$ to 1:1) to afford 230.8 mg of metronidazole maleimide **2s** as a white sticky solid in 58% yield.

2-(2-Methyl-5-nitro-1*H*-imidazol-1-yl)ethyl

2s

3-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoate (2s)



2s


230.8 mg (58%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 2:1$ to 1:1); white sticky solid; ^1H NMR (500 MHz, CDCl_3) δ 7.95 (s, 1H), 6.69 (s, 2H), 4.59 (t, $J = 5.5$ Hz, 2H), 4.40 (t, $J = 5.5$ Hz, 2H), 3.78 (t, $J = 7.0$ Hz, 2H), 2.59 (t, $J = 7.0$ Hz, 2H), 2.52 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 170.3, 170.2, 150.8, 134.4, 132.9, 63.0, 45.0, 33.6, 32.9, 14.4; IR (KBr) ν 3059, 2956, 1739, 1707, 1529, 1465, 1427, 1363, 1263, 1186, 1145, 1076, 1041, 825 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{13}\text{H}_{14}\text{N}_4\text{O}_6$ 322.0913; Found 322.0911.

General procedure for the spiroannulation of *N*-aryl indazol-3-ols with maleimides and maleates (3aa**, **3a–3n**, **4b–4m**, and **4o–4t**)**

To an oven-dried sealed tube charged with 1-phenyl-1*H*-indazol-3-ol (**1a**) (42.1 mg, 0.2 mmol, 100 mol %), [RhCp^{*}Cl₂]₂ (3.1 mg, 0.005 mmol, 2.5 mol %), AgSbF₆ (13.7 mg, 0.04 mmol, 20 mol %), NaOAc (8.2 mg, 0.1 mmol, 50 mol %), and *N*-methyl maleimide (**2a**) (44.4 mg, 0.4 mmol, 200 mol %) was added MeCN (1 mL) under air at room temperature. The reaction mixture was allowed to stir in an oil bath for 20 h at 80 °C. The reaction mixture was cooled to room temperature, diluted with EtOAc (2 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (CH₂Cl₂/EtOAc = 7:1 to 4:1) to afford **3a** (58.2 mg) in 91% yield.

Characterization data for all products (3aa, 3a–3n, 4b–4m, and 4o–4t)


3-(2-(3-Hydroxy-1*H*-indazol-1-yl)phenyl)-1-methylpyrrolidine-2,5-dione (3aa)



3aa

16.2 mg (25%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 4:1$ to $1:1$); light brown solid; mp = 103.4–106.2 °C; ^1H NMR (500 MHz, CD_3COCD_3) δ 9.83 (brs, 1H), 7.72 (dt, $J = 8.0, 1.0$ Hz, 1H), 7.51–7.45 (m, 3H), 7.42–7.38 (m, 2H), 7.23 (d, $J = 8.5$ Hz, 1H), 7.14 (t, $J = 7.5$ Hz, 1H), 4.27 (dd, $J = 10.0, 5.5$ Hz, 1H), 3.06 (dd, $J = 18.0, 9.5$ Hz, 1H), 2.73 (dd, $J = 18.0, 5.5$ Hz, 1H), 2.71 (s, 3H); ^{13}C NMR (125 MHz, CD_3COCD_3) δ 178.2, 176.5, 156.9, 143.3, 139.6, 137.4, 131.4, 129.4, 129.3, 128.8, 128.3, 121.0, 120.8, 114.6, 111.0, 44.1, 38.6, 24.8; IR (KBr) ν 3056, 1776, 1718, 1616, 1540, 1500, 1438, 1380, 1282, 1228, 1118, 954 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_3$ 321.1113; Found 321.1114.

1'-Methyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3a)




3a

58.2 mg (91%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $4:1$); white solid; mp = 272.8–275.8 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.91 (dt, $J = 8.0, 1.2$ Hz, 1H), 7.67 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.52 (dt, $J = 8.4, 0.8$ Hz, 1H), 7.49 (ddd, $J = 9.6, 6.8, 1.6$ Hz, 1H), 7.36 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.25 (ddd, $J = 8.8, 7.2, 0.8$ Hz, 1H), 7.19–7.12 (m, 2H), 4.02 (d, $J = 18.0$ Hz, 1H), 3.22 (s, 3H), 3.21 (d, $J = 18.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.0, 172.4, 161.0, 141.9, 137.4, 133.4, 131.1, 130.6, 125.2, 124.0, 122.6, 122.4, 119.6, 110.8, 109.7, 66.9, 40.3, 26.0; IR (KBr) ν


3054, 2925, 2360, 1714, 1660, 1600, 1496, 1467, 1432, 1375, 1361, 1313, 1267, 1139, 890 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₁₈H₁₃N₃O₃ 319.0957; Found 319.0955.

8-Methoxy-1'-methyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3b)



55.9 mg (80%); eluent (CH₂Cl₂/EtOAc = 7:1 to 4:1); pale yellow solid; mp = 168.8–171.6 °C; mp = 152.2–155.3 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (dt, *J* = 7.6, 1.2 Hz, 1H), 7.62 (ddd, *J* = 9.6, 7.2, 1.2 Hz, 1H), 7.43 (dt, *J* = 8.4, 0.8 Hz, 1H), 7.26 (d, *J* = 8.8 Hz, 1H), 7.19 (ddd, *J* = 8.8, 7.2, 0.8 Hz, 1H), 6.98 (dd, *J* = 8.8, 2.8 Hz, 1H), 6.67 (d, *J* = 2.4 Hz, 1H), 3.96 (d, *J* = 18.4 Hz, 1H), 3.78 (s, 3H), 3.20 (s, 3H), 3.19 (d, *J* = 18.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 172.3, 161.5, 156.9, 142.6, 133.3, 131.6, 131.5, 125.1, 122.2, 119.1, 116.3, 110.6, 110.5, 108.3, 67.1, 56.2, 40.2, 25.9; IR (KBr) ν 3054, 2989, 1791, 1712, 1666, 1617, 1494, 1459, 1432, 1378, 1282, 1267, 1220, 1141, 1078, 1024, 983, 804 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₁₉H₁₅N₃O₄ 349.1063; Found 349.1061.


1',8-Dimethyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3c)



54.7 mg (82%); eluent (CH₂Cl₂/EtOAc = 7:1 to 4:1); pale yellow solid; mp = 224.4–227.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (dt, *J* = 8.0, 0.8 Hz, 1H), 7.64 (ddd, *J* = 9.6, 7.2, 1.2 Hz,


1H), 7.48 (d, J = 8.4 Hz, 1H), 7.28–7.19 (m, 3H), 6.95 (s, 1H), 3.99 (d, J = 18.0 Hz, 1H), 3.20 (s, 3H), 3.19 (d, J = 18.0 Hz, 1H), 2.35 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.1, 172.5, 161.1, 142.1, 135.2, 134.1, 133.3, 131.6, 130.7, 125.1, 122.7, 122.4, 119.4, 110.7, 109.5, 66.9, 40.3, 25.9, 21.1; IR (KBr) ν 3054, 2987, 1791, 1714, 1670, 1614, 1500, 1461, 1434, 1378, 1284, 1267, 1141, 983, 804 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{19}\text{H}_{15}\text{N}_3\text{O}_3$ 333.1113; Found 333.1113.

**8-Chloro-1'-methyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione
(3d)**




61.6 mg (87%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc}$ = 6:1 to 4:1); pale orange solid; mp = 236.5–239.2 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.87 (dt, J = 7.6, 1.2 Hz, 1H), 7.65 (ddd, J = 9.6, 7.2, 1.2 Hz, 1H), 7.45 (dt, J = 8.4, 0.8 Hz, 1H), 7.42 (dd, J = 8.4, 2.0 Hz, 1H), 7.27–7.22 (m, 2H), 7.14 (d, J = 2.0 Hz, 1H), 3.97 (d, J = 18.4 Hz, 1H), 3.21 (s, 3H), 3.20 (d, J = 18.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.5, 171.9, 161.1, 141.9, 136.0, 133.6, 131.9, 131.2, 129.1, 125.2, 122.9, 122.8, 119.6, 110.8, 110.5, 66.8, 40.3, 26.1; IR (KBr) ν 3054, 2987, 1793, 1718, 1679, 1619, 1606, 1494, 1428, 1380, 1346, 1267, 1082, 820 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{18}\text{H}_{12}\text{ClN}_3\text{O}_3$ 353.0567; Found 353.0563.

**8-Fluoro-1'-methyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione
(3e)**



54.2 mg (80%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 6:1$ to $4:1$); pale orange solid; mp = 221.2–224.1 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.88 (dt, $J = 8.0, 1.2$ Hz, 1H), 7.66 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.46 (dt, $J = 8.4, 0.8$ Hz, 1H), 7.29 (dd, $J = 8.8, 4.0$ Hz, 1H), 7.24 (ddd, $J = 8.8, 7.2, 0.8$ Hz, 1H), 7.19 (td, $J = 8.8, 2.4$ Hz, 1H), 6.91 (dd, $J = 7.6, 2.4$ Hz, 1H), 3.98 (d, $J = 18.8$ Hz, 1H), 3.21 (s, 3H), 3.20 (d, $J = 18.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.5, 171.9, 161.6, 159.3 (d, $J_{\text{C}-\text{F}} = 243.7$ Hz), 142.6, 134.1 (d, $J_{\text{C}-\text{F}} = 2.2$ Hz), 133.5, 131.7 (d, $J_{\text{C}-\text{F}} = 8.1$ Hz), 125.2, 122.8, 117.9 (d, $J_{\text{C}-\text{F}} = 24.0$ Hz), 110.7, 110.6, 110.4 (d, $J_{\text{C}-\text{F}} = 13.4$ Hz), 110.2, 67.0 (d, $J_{\text{C}-\text{F}} = 2.5$ Hz), 40.3, 26.0; ^{19}F NMR (376 MHz, CDCl_3) δ -117.3 (s); IR (KBr) ν 3070, 3019, 1791, 1718, 1680, 1540, 1490, 1461, 1410, 1378, 1351, 1284, 1209, 1166, 1141, 985, 902, 808 cm⁻¹; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{18}\text{H}_{12}\text{FN}_3\text{O}_3$ 337.0863; Found 337.0864.


1'-Methyl-8-(trifluoromethyl)-12H-spiro[indazolo[1,2-a]indazole-10,3'-pyrrolidine]-2',5',12-trione (3f)



60.4 mg (78%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $4:1$); yellow solid; mp = 221.9–224.7 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.90 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.73 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.70 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.53 (d, $J = 8.0$ Hz, 1H), 7.41 (d, $J = 7.2$ Hz, 1H), 7.39 (s, 1H), 7.29 (t, $J = 7.2$ Hz, 1H), 3.98 (d, $J = 18.4$ Hz, 1H), 3.25 (d, $J = 18.4$ Hz, 1H), 3.23 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.4, 171.8, 160.9, 141.3, 139.6, 133.7, 131.0, 128.9 (q, $J_{\text{C}-\text{F}} = 3.9$ Hz), 126.0 (q, $J_{\text{C}-\text{F}} = 33.3$ Hz), 125.3, 123.6 (q, $J_{\text{C}-\text{F}} = 270.1$ Hz), 123.5, 119.9, 119.8 (q, $J_{\text{C}-\text{F}} =$


3.7 Hz), 110.9, 109.4, 66.8, 40.4, 26.1; ^{19}F NMR (376 MHz, CDCl_3) δ -61.6 (s); IR (KBr) ν 3060, 2921, 2852, 2653, 2373, 2254, 1700, 1677, 1604, 1502, 1482, 1459, 1430, 1375, 1319, 1284, 1190, 1168, 1114, 1054, 1020, 981, 946, 908, 815 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{19}\text{H}_{12}\text{F}_3\text{N}_3\text{O}_3$ 387.0831; Found 387.0832.

1'-Methyl-8-nitro-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3g)




64.2 mg (88%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 6:1$ to $4:1$); yellow solid; mp = > 300 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.42 (dt, $J = 8.8, 2.0$ Hz, 1H), 8.90 (d, $J = 2.0$ Hz, 1H), 7.93 (dt, $J = 8.0, 1.2$ Hz, 1H), 7.73 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.55 (dt, $J = 8.4, 0.8$ Hz, 1H), 7.37 (d, $J = 8.8$ Hz, 1H), 7.36 (t, $J = 7.2$ Hz, 1H), 3.97 (d, $J = 18.4$ Hz, 1H), 3.29 (d, $J = 18.8$ Hz, 1H), 3.24 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.9, 171.5, 160.4, 143.3, 140.8, 140.2, 134.0, 131.3, 128.2, 125.5, 124.2, 120.4, 119.1, 110.9, 108.5, 66.6, 40.4, 26.3; IR (KBr) ν 3019, 2925, 1793, 1708, 1673, 1596, 1517, 1494, 1459, 1436, 1378, 1321, 1288, 1214, 1133, 1110, 985, 854 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{18}\text{H}_{12}\text{N}_4\text{O}_5$ 364.0808; Found 364.0807.

7-Chloro-1'-methyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3h)




50.9 mg (72%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $4:1$); pale yellow solid; mp = 238.4–241.2 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.90 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.69 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.50 (d, $J = 8.4$ Hz, 1H), 7.32 (s, 1H), 7.27 (t, $J = 8.0$ Hz, 1H), 7.11–7.07 (m, 2H), 3.98 (d, $J = 18.4$ Hz, 1H), 3.20 (s, 3H), 3.19 (d, $J = 18.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.7, 172.0, 161.1, 141.7, 138.3, 137.2, 133.6, 128.9, 125.3, 123.9, 123.3, 123.2, 119.8, 110.9, 110.1, 66.8, 40.3, 26.0; IR (KBr) ν 3054, 2987, 1791, 1716, 1679, 1604, 1494, 1465, 1432, 1380, 1267, 1145, 1053, 810 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{18}\text{H}_{12}\text{ClN}_3\text{O}_3$ 353.0567; Found 353.0567.

1'-Methyl-7-(trifluoromethyl)-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3i)




39.6 mg (51%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $4:1$); pale yellow solid; mp = 199.9–202.8 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.91 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.69 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.56 (dt, $J = 8.4, 0.8$ Hz, 1H), 7.53 (t, $J = 0.4$ Hz, 1H), 7.39 (dq, $J = 8.4, 0.8$ Hz, 1H), 7.32–7.28 (m, 2H), 3.99 (d, $J = 18.0$ Hz, 1H), 3.23 (d, $J = 18.4$ Hz, 1H), 3.22 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.5, 171.7, 161.2, 141.9, 137.9, 133.9 (q, $J_{\text{C}-\text{F}} = 1.3$ Hz), 133.8, 133.7 (q, $J_{\text{C}-\text{F}} = 30.5$ Hz), 125.3, 123.5, 123.4 (q, $J_{\text{C}-\text{F}} = 271.5$ Hz), 123.0, 120.8 (q, $J_{\text{C}-\text{F}} = 3.7$ Hz), 119.8, 111.1, 106.5 (q, $J_{\text{C}-\text{F}} = 3.8$ Hz), 66.9, 40.5, 26.1; ^{19}F NMR (376 MHz, CDCl_3) δ –62.7 (s); IR (KBr) ν 2919, 2850, 1791, 1740, 1642, 1612, 1504, 1436, 1378, 1280, 1210, 1168, 1110, 1060, 979, 964, 910, 829 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{19}\text{H}_{12}\text{F}_3\text{N}_3\text{O}_3$ 387.0831; Found 387.0832.

1'-Methyl-7-nitro-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3j)



36.5 mg (50%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 6:1$ to $4:1$); yellow solid; mp = 270.1–273.2 °C; ^1H NMR (400 MHz, DMSO- d_6) δ 8.48–8.47 (m, 1H), 8.23 (dd, $J = 8.4, 1.6$ Hz, 1H), 8.08–8.03 (m, 2H), 7.85–7.80 (m, 2H), 7.38 (td, $J = 7.2, 0.8$ Hz, 1H), 3.79 (d, $J = 18.4$ Hz, 1H), 3.52 (d, $J = 18.4$ Hz, 1H), 3.04 (s, 3H); ^{13}C NMR (100 MHz, DMSO- d_6) δ 173.2, 172.0, 159.9, 149.8, 141.2, 137.7, 136.4, 133.8, 125.6, 124.0, 123.5, 119.0, 118.9, 112.4, 104.3, 66.8, 40.0, 25.4; IR (KBr) ν 2256, 1741, 1710, 1652, 1533, 1490, 1461, 1432, 1394, 1351, 1292, 1047, 1010, 823 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{18}\text{H}_{12}\text{N}_4\text{O}_5$ 364.0808; Found 364.0804.


**6-Fluoro-1'-methyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione
(3k)**



23.7 mg (35%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $4:1$); pale yellow solid; mp = 266.8–269.8 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.76 (dq, $J = 8.4, 0.8$ Hz, 1H), 7.65 (ddd, $J = 10.0, 7.2, 1.2$ Hz, 1H), 7.28–7.23 (m, 2H), 7.10 (td, $J = 7.6, 4.0$ Hz, 1H), 6.95 (dd, $J = 7.6, 0.8$ Hz, 1H), 3.95 (d, $J = 18.4$ Hz, 1H), 3.22 (d, $J = 18.4$ Hz, 1H), 3.21 (s, 3H); ^{13}C NMR (175 MHz, CDCl_3) δ 172.7, 172.1, 161.5, 147.4 (d, $J_{\text{C}-\text{F}} = 245.7$ Hz), 142.5, 133.7 (d, $J_{\text{C}-\text{F}} = 2.2$ Hz), 133.5 (d, $J_{\text{C}-\text{F}} = 3.3$ Hz), 125.6, 125.5, 125.2 (d, $J_{\text{C}-\text{F}} = 6.4$ Hz), 123.0 (d, $J_{\text{C}-\text{F}} = 0.8$ Hz), 119.6, 118.5 (d, $J_{\text{C}-\text{F}} = 19.1$ Hz), 118.1 (d, $J_{\text{C}-\text{F}} = 3.5$ Hz), 112.9 (d, $J_{\text{C}-\text{F}} = 14.6$ Hz), 66.9, 40.8, 26.0; ^{19}F NMR (376 MHz, CDCl_3) δ -125.1 (s); IR (KBr) ν 3054, 1793, 1716, 1679, 1614, 1494,

1434, 1380, 1348, 1282, 1140, 1012, 820 cm⁻¹; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₁₈H₁₂FN₃O₃ 337.0863; Found 337.0865.


1',2-Dimethyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3m)



3m

60.8 mg (91%); eluent (CH₂Cl₂/EtOAc = 6:1 to 4:1); light orange solid; mp = 205.2–208.1 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (s, 1H), 7.46–7.42 (m, 2H), 7.38 (d, *J* = 8.4 Hz, 1H), 7.29 (d, *J* = 8.4 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.08 (t, *J* = 7.0 Hz, 1H), 3.98 (d, *J* = 18.2 Hz, 1H), 3.18 (d, *J* = 18.9 Hz, 1H), 3.17 (s, 3H), 2.41 (s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) δ 172.9, 172.4, 161.2, 140.7, 137.6, 134.8, 132.5, 131.0, 130.4, 124.4, 123.6, 122.2, 119.7, 110.6, 109.5, 66.9, 40.3, 25.9, 21.1; IR (KBr) ν 3059, 2987, 1714, 1668, 1504, 1471, 1433, 1379, 1282, 1144, 987 cm⁻¹; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₁₉H₁₅N₃O₃ 333.1113; Found 333.1116.

1'-Methyl-2-nitro-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (3n)




3n

53.2 mg (73%); eluent (CH₂Cl₂/EtOAc = 7:1 to 1:1); orange solid; mp = 284.3–286.9 °C; ¹H NMR (400 MHz, DMSO-d₆) δ 8.57 (d, *J* = 2.4 Hz, 1H), 8.52 (dd, *J* = 9.2, 2.4 Hz, 1H), 8.21 (d, *J* = 8.8 Hz, 1H), 7.98 (d, *J* = 8.0 Hz, 1H), 7.81 (d, *J* = 7.6 Hz, 1H), 7.63 (td, *J* = 7.6, 1.2 Hz, 1H), 7.32 (td, *J* = 7.6, 0.8 Hz, 1H), 3.78 (d, *J* = 18.8 Hz, 1H), 3.48 (d, *J* = 18.4 Hz, 1H), 3.05 (s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) δ 173.2, 172.3, 157.1, 141.5, 140.0, 134.5, 131.1, 130.4,

128.0, 125.2, 124.5, 121.0, 117.8, 111.5, 110.3, 66.8, 40.1, 25.4; IR (KBr) ν 3057, 2927, 1720, 1685, 1622, 1601, 1520, 1495, 1468, 1431, 1371, 1335, 1317, 1269, 1151, 1117 cm^{-1} ; HRMS (ion trap, FAB) m/z: [M + H]⁺ Calcd for C₁₈H₁₃N₄O₅ 365.0886; Found 365.0886.


1'-Ethyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4b)



4b

58.2 mg (87%); eluent (CH₂Cl₂/EtOAc = 7:1 to 4:1); pale yellow solid; mp = 196.5–199.6 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.89 (dt, *J* = 8.0, 1.2 Hz, 1H), 7.65 (ddd, *J* = 9.6, 7.2, 1.2 Hz, 1H), 7.50 (d, *J* = 8.4 Hz, 1H), 7.47 (ddd, *J* = 8.0, 6.0, 2.8 Hz, 1H), 7.34 (dt, *J* = 8.4, 0.8 Hz, 1H), 7.23 (ddd, *J* = 8.8, 7.2, 0.8 Hz, 1H), 7.15–7.10 (m, 2H), 3.98 (d, *J* = 18.4 Hz, 1H), 3.77 (q, *J* = 7.2 Hz, 2H), 3.18 (d, *J* = 18.4 Hz, 1H), 1.30 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.7, 172.0, 160.9, 141.8, 137.2, 133.3, 131.1, 130.7, 125.1, 123.9, 122.5, 122.2, 119.6, 110.7, 109.6, 66.8, 40.4, 35.1, 13.1; IR (KBr) ν 3653, 3622, 3572, 3531, 3485, 2979, 2937, 1788, 1740, 1692, 1580, 1460, 1411, 1323, 1379, 1243, 1110, 1033, 893 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₁₉H₁₅N₃O₃ 333.1113; Found 333.1112.

1'-Cyclohexyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4c)




4c

60.5 mg (78%); eluent (CH₂Cl₂/EtOAc = 7:1 to 4:1); pale yellow solid; mp = 203.0–205.2 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (dt, *J* = 8.0, 0.8 Hz, 1H), 7.65 (ddd, *J* = 9.6, 7.2, 1.2 Hz, 1H), 7.49 (dt, *J* = 8.4, 0.8 Hz, 1H), 7.49–7.45 (m, 1H), 7.33 (dt, *J* = 8.0, 0.8 Hz, 1H), 7.23 (ddd,

$J = 9.2, 7.6, 1.2$ Hz, 1H), 7.13–7.12 (m, 2H), 4.18–4.11 (m, 1H), 3.93 (d, $J = 18.0$ Hz, 1H), 3.15 (d, $J = 18.0$ Hz, 1H), 2.29–2.11 (m, 2H), 1.87–1.75 (m, 4H), 1.68–1.62 (m, 2H), 1.36–1.32 (m, 1H), 1.31–1.18 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.0, 172.2, 161.1, 141.9, 137.3, 133.3, 131.0, 130.9, 125.2, 123.9, 122.5, 122.0, 119.7, 110.8, 109.6, 66.5, 53.2, 40.4, 29.1, 28.9, 25.9, 25.8, 25.1; IR (KBr) ν 3059, 2931, 2856, 1756, 1711, 1670, 1920, 1600, 1491, 1468, 1396, 1365, 1344, 1306, 1259, 1196, 1149, 1120, 1036, 945 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{23}\text{H}_{21}\text{N}_3\text{O}_3$ 387.1583; Found 387.1580.


1'-(*tert*-Butyl)-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4d)



4d

44.8 mg (62%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 6:1$ to 4:1); pale orange solid; mp = 191.1–194.0 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.91 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.65 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.34 (d, $J = 8.0$ Hz, 1H), 7.50–7.45 (m, 2H), 7.23 (ddd, $J = 9.2, 7.2, 0.8$ Hz, 1H), 7.17–7.11 (m, 2H), 3.95 (d, $J = 18.0$ Hz, 1H), 3.09 (d, $J = 18.0$ Hz, 1H), 1.67 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.9, 173.1, 161.0, 141.5, 137.1, 133.2, 131.1, 130.9, 125.2, 123.8, 122.4, 121.8, 119.8, 110.6, 109.6, 66.9, 60.3, 40.3, 28.5; IR (KBr) ν 1714, 1671, 1621, 1602, 1490, 1463, 1396, 1338, 1303, 1253, 1174, 1027, 1000 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{21}\text{H}_{19}\text{N}_3\text{O}_3$ 361.1426; Found 361.1421.


1'-Benzyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4e)



4e


57.1 mg (72%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $4:1$); pale yellow solid; mp = 196.7–199.5 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.92 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.66 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.49 (dt, $J = 8.4, 0.8$ Hz, 1H), 7.45–7.40 (m, 3H), 7.36–7.30 (m, 4H), 7.24 (ddd, $J = 8.8, 7.2, 0.8$ Hz, 1H), 7.03 (td, $J = 7.6, 1.2$ Hz, 1H), 6.88 (dt, $J = 8.0, 0.8$ Hz, 1H), 4.86 (q, $J = 14.0$ Hz, 2H), 4.05 (d, $J = 18.0$ Hz, 1H), 3.17 (d, $J = 18.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.4, 171.9, 161.0, 141.9, 137.2, 135.3, 133.4, 131.1, 130.7, 128.9, 128.6, 128.3, 125.2, 123.9, 122.6, 122.1, 119.7, 110.7, 109.6, 66.9, 43.5, 40.3; IR (KBr) ν 3060, 2927, 1792, 1771, 1720, 1622, 1603, 1493, 1468, 1431, 1392, 1344, 1309, 1250, 1176, 1119, 943 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{24}\text{H}_{17}\text{N}_3\text{O}_3$ 395.1270; Found 395.1270.

1'-Phenyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4f)




49.6 mg (65%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 6:1$ to $4:1$); orange solid; mp = 239.5–242.4 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.91 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.67 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.53–7.40 (m, 7H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.31 (d, $J = 7.6$ Hz, 1H), 7.25 (ddd, $J = 9.2, 7.2, 1.2$ Hz, 1H), 7.18 (td, $J = 7.6, 0.8$ Hz, 1H), 4.16 (d, $J = 18.4$ Hz, 1H), 3.39 (d, $J = 18.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.9, 171.4, 161.4, 142.1, 137.5, 133.4, 131.7, 131.2, 130.5, 129.4, 129.3, 126.7, 125.2, 124.0, 122.7, 122.4, 119.6, 110.9, 109.8, 66.9, 40.6; IR (KBr) ν 2924, 2852, 1792, 1780, 1719, 1642, 1580, 1532, 1410, 1380, 1278, 1028, 980, 820 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{23}\text{H}_{15}\text{N}_3\text{O}_3$ 381.1113; Found 381.1114.

1'-(4-Fluorophenyl)-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4g)



57.6 mg (72%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $4:1$); pale yellow solid; mp = 207.4–210.0 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.83 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.60 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.46–7.41 (m, 2H), 7.37 (dq, $J = 9.2, 2.0$ Hz, 2H), 7.29 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.22 (d, $J = 7.2$ Hz, 1H), 7.16 (ddd, $J = 8.8, 6.0, 0.8$ Hz, 1H), 7.14–7.08 (m, 3H), 4.04 (d, $J = 18.4$ Hz, 1H), 3.32 (d, $J = 18.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.9, 171.4, 162.7 (d, $J_{\text{C}-\text{F}} = 247.8$ Hz), 161.5, 142.3, 137.6, 133.5, 131.3, 130.3, 128.6 (d, $J_{\text{C}-\text{F}} = 8.8$ Hz), 127.6, 127.5 (d, $J_{\text{C}-\text{F}} = 3.3$ Hz), 125.2, 124.1, 122.5 (d, $J_{\text{C}-\text{F}} = 35.5$ Hz), 119.6, 116.4 (d, $J_{\text{C}-\text{F}} = 22.9$ Hz), 110.9, 109.8, 66.9, 40.7; ^{19}F NMR (376 MHz, CDCl_3) δ –111.4 (s); IR (KBr) ν 3057, 2991, 1793, 1726, 1674, 1622, 1603, 1508, 1495, 1467, 1383, 1350, 1265, 1196, 1155, 1080, 835 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{23}\text{H}_{14}\text{FN}_3\text{O}_3$ 399.1019; Found 399.1017.


1'-(4-Nitrophenyl)-12H-spiro[indazolo[1,2-a]indazole-10,3'-pyrrolidine]-2',5',12-trione (4h)



41.9 mg (49%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 6:1$ to $4:1$); yellow solid; mp = 187.2–190.3 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.34 (dt, $J = 9.2, 2.8$ Hz, 2H), 7.91 (dt, $J = 8.0, 1.2$ Hz, 1H), 7.72 (dt, $J = 9.2, 2.8$ Hz, 2H), 7.69 (ddd, $J = 8.4, 6.0, 0.8$ Hz, 1H), 7.56–7.51 (m, 2H), 7.39 (dt, $J = 8.4, 0.8$ Hz, 1H), 7.32 (d, $J = 7.6$ Hz, 1H), 7.27 (ddd, $J = 8.8, 7.2, 0.8$ Hz, 1H), 7.19 (td, $J = 7.6, 1.2$ Hz, 1H), 4.13 (d, $J = 18.8$ Hz, 1H), 3.45 (d, $J = 18.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.1, 170.9, 161.8, 147.6, 142.5, 137.7, 137.1, 133.7, 131.5, 129.8, 127.4, 125.2, 124.7, 124.2, 122.9, 122.5, 119.5, 111.0, 109.9, 66.9, 40.8; IR (KBr) ν 3055, 2989, 1795, 1728, 1672, 1601, 1523, 1493, 1468, 1375, 1344, 1306, 1267, 1186, 1050, 845 cm^{-1} ; HRMS (quadrupole, EI) m/z:

[M]⁺ Calcd for C₂₃H₁₄N₄O₅ 426.0964; Found 426.0966.


1'-Allyl-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4i)



4i

40.1 mg (58%); eluent (CH₂Cl₂/EtOAc = 6:1 to 4:1); pale orange solid; mp = 167.1–170.0 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (ddd, *J* = 9.6, 7.2, 1.2 Hz, 1H), 7.89 (dt, *J* = 8.0, 0.8 Hz, 1H), 7.50 (dt, *J* = 8.4, 1.2 Hz, 1H), 7.47 (ddd, *J* = 9.6, 6.8, 0.8 Hz, 1H), 7.34 (dt, *J* = 8.0, 0.8 Hz, 1H), 7.23 (ddd, *J* = 8.8, 7.2, 0.8 Hz, 1H), 7.17–7.11 (m, 2H), 5.88 (ddt, *J* = 17.2, 10.2, 5.6 Hz, 1H), 5.39 (dq, *J* = 16.8, 1.2 Hz, 1H), 5.28 (dq, *J* = 10.2, 1.2 Hz, 1H), 4.30 (dt, *J* = 5.6, 1.6 Hz, 2H), 4.03 (d, *J* = 18.4 Hz, 1H), 3.22 (d, *J* = 18.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 172.4, 171.8, 160.9, 141.7, 137.2, 133.3, 131.1, 130.6, 129.9, 125.2, 123.9, 122.5, 122.2, 119.6, 119.1, 110.7, 109.6, 66.8, 41.9, 40.3; IR (KBr) ν 3057, 2927, 1788, 1712, 1657, 1620, 1599, 1401, 1466, 1429, 1367, 1356, 1329, 1265, 1180, 1151, 1120, 995, 943, 862 cm⁻¹; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₂₀H₁₅N₃O₃ 345.1113; Found 345.1114.

Methyl (2*S*)-2-(2',5',12-trioxo-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidin]-1'-yl)propanoate (4j)




4j

49.4 mg (63%, dr = 1:1); eluent (CH₂Cl₂/EtOAc = 6:1 to 4:1); pale yellow solid; mp = 102.9–105.6 °C; ¹H NMR (400 MHz, CDCl₃) **diastereomer A:** δ 7.90–7.87 (m, 1H), 7.67–7.62 (m, 1H), 7.51–7.48 (m, 1H), 7.45 (d, *J* = 7.6 Hz, 1H), 7.37–7.31 (m, 2H), 7.26–7.20 (m, 1H),


7.17–7.12 (m, 1H), 5.05 (q, J = 7.2 Hz, 1H), 4.03 (d, J = 18.4 Hz, 1H), 3.82 (s, 3H), 3.25 (d, J = 18.4 Hz, 1H), 1.75 (d, J = 5.6 Hz, 3H); **diastereomer B:** δ 7.90–7.87 (m, 1H), 7.67–7.62 (m, 1H), 7.51–7.48 (m, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.37–7.31 (m, 2H), 7.26–7.20 (m, 1H), 7.17–7.12 (m, 1H), 4.92 (q, J = 7.2 Hz, 1H), 4.02 (d, J = 18.4 Hz, 1H), 3.71 (s, 3H), 3.20 (d, J = 18.0 Hz, 1H), 1.73 (d, J = 5.2 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) **diastereomer A:** δ 172.0, 171.4, 169.4, 161.1, 142.1, 137.2, 133.4, 131.1, 130.7, 125.1, 124.1, 122.8, 122.6, 119.5, 110.8, 109.5, 66.9, 53.1, 49.6, 40.4, 14.5; **diastereomer B:** δ 171.8, 171.3, 169.3, 161.0, 142.0, 137.1, 133.3, 131.0, 130.6, 125.0, 124.0, 122.7, 122.5, 119.5, 110.7, 109.5, 66.4, 53.0, 49.1, 40.3, 14.4; IR (KBr) ν 2829, 1791, 1747, 1722, 1673, 1621, 1602, 1490, 1463, 1434, 1390, 1359, 1309, 1251, 1209, 1060, 1027, 1002, 946, 871 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{21}\text{H}_{17}\text{N}_3\text{O}_5$ 391.1168; Found 391.1169.

12*H*-Spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4k)




31.8 mg (52%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc}$ = 8:1 to 3:1); white solid; mp = 267.0–270.2 °C; ^1H NMR (500 MHz, DMSO-d₆) δ 12.1 (brs, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.81–7.45 (m, 3H), 7.63 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.28 (t, J = 7.5 Hz, 1H), 7.19 (t, J = 7.5 Hz, 1H), 3.65 (d, J = 18.5 Hz, 1H), 3.36 (d, J = 18.5 Hz, 1H); ^{13}C NMR (125 MHz, DMSO-d₆) δ 174.6, 173.9, 159.7, 104.9, 136.4, 133.4, 1130.7, 130.3, 124.0, 123.8, 123.6, 122.4, 118.6, 111.5, 109.6, 67.9, 41.0; IR (KBr) ν 2954, 2919, 1791, 1739, 1710, 1639, 1606, 1506, 1459, 1390, 1309, 1251, 1187, 1114, 1074, 1035, 997, 889 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{17}\text{H}_{11}\text{N}_3\text{O}_3$ 305.0800; Found 305.0800.

1'-(2-(2,5-Dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)ethyl)-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione (4l)



27.5 mg (32%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 8:1$ to $3:1$); light yellow solid; mp = 237.6–240.5 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.85 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.65 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.59 (dt, $J = 7.6, 0.8$ Hz, 1H), 7.51–7.46 (m, 2H), 7.33 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.24–7.18 (m, 2H), 6.69 (s, 2H), 4.01–3.95 (m, 1H), 3.92–3.78 (m, 4H), 3.20 (d, $J = 18.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.1, 172.4, 170.9, 160.8, 141.9, 137.5, 134.4, 133.3, 131.0, 130.2, 125.1, 124.1, 123.8, 122.6, 119.5, 110.8, 109.4, 66.7, 40.6, 38.9, 36.3; IR (KBr) ν 2925, 2854, 1789, 1740, 1780, 1600, 1490, 1467, 1434, 1390, 1355, 1334, 1247, 1201, 1151, 1118, 1031, 975, 939, 896, 827 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{23}\text{H}_{16}\text{N}_4\text{O}_5$ 428.1121; Found 428.1121.


1',1'''-(Ethane-1,2-diyl)bis(12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidine]-2',5',12-trione) (4m)



85.5 mg (67%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 6:1$ to $2:1$); yellow solid; mp = 278.0–281.0 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.89–7.85 (m, 2H), 7.70–7.65 (m, 2H), 7.54–7.50 (m, 3H), 7.49 (d, $J = 8.8$ Hz, 1H), 7.46–7.40 (m, 2H), 7.32 (dd, $J = 8.4, 2.4$ Hz, 2H), 7.26–7.22 (m, 2H), 7.07 (td, $J = 7.6, 1.2$ Hz, 1H), 6.96 (td, $J = 7.6, 1.2$ Hz, 1H), 4.18–4.12 (m, 2H), 4.00–3.93 (m, 2H), 3.85 (d, $J = 18.4$ Hz, 2H), 3.44 (d, $J = 18.4$ Hz, 1H), 3.17 (d, $J = 18.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.6, 172.1, 161.1, 142.0, 137.3, 133.4, 130.9, 130.2, 125.1, 124.2, 123.9,


122.5, 119.5, 110.9, 109.2, 67.3, 41.8, 38.4; IR (KBr) ν 3480, 2927, 1789, 1716, 1668, 1621, 1600, 1490, 1465, 1392, 1353, 1305, 1261, 1214, 1168, 1116, 1085, 1031, 943, 910, 860 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₃₆H₂₄N₆O₆ 636.1757; Found 636.1753.

Butyl 10-(2-butoxy-2-oxoethyl)-12-oxo-10*H*,12*H*-indazolo[1,2-*a*]indazole-10-carboxylate (4o)




44.8 mg (51%); eluent (CH₂Cl₂/EtOAc = 7:1 to 4:1); yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (dt, *J* = 8.0, 1.2 Hz, 1H), 7.63 (ddd, *J* = 9.6, 7.2, 1.2 Hz, 1H), 7.49 (dt, *J* = 8.4, 0.8 Hz, 1H), 7.45–7.35 (m, 2H), 7.29 (dt, *J* = 8.0, 0.8 Hz, 1H), 7.19 (ddd, *J* = 8.8, 7.2, 0.8 Hz, 1H), 7.07 (td, *J* = 7.6, 0.8 Hz, 1H), 4.21–4.10 (m, 3H), 3.75 (t, *J* = 6.8 Hz, 2H), 3.59 (d, *J* = 16.8 Hz, 1H), 1.56–1.49 (m, 2H), 1.25–1.14 (m, 4H), 1.09–1.00 (m, 2H), 0.79 (t, *J* = 7.2 Hz, 3H), 0.71 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.5, 167.9, 160.3, 140.3, 137.0, 132.6, 130.5, 130.4, 125.0, 123.5, 123.0, 121.8, 119.9, 110.2, 108.6, 68.0, 67.0, 64.8, 36.9, 30.4, 30.3, 19.0, 18.9, 13.7, 13.6; IR (KBr) ν 2958, 2933, 2871, 1735, 1671, 1619, 1600, 1492, 1465, 1394, 1353, 1305, 1245, 1226, 1189, 1058, 1024, 946 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for C₂₅H₂₈N₂O₅ 436.1998; Found 436.1993.

Ethyl 10-(2-ethoxy-2-oxoethyl)-12-oxo-10*H*,12*H*-indazolo[1,2-*a*]indazole-10-carboxylate (4p)




36.3 mg (48%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $5:1$); orange sticky solid; ^1H NMR (500 MHz, CDCl_3) δ 7.91 (dt, $J = 8.0, 1.0$ Hz, 1H), 7.62 (ddd, $J = 10.0, 7.5, 1.5$ Hz, 1H), 7.48 (dt, $J = 8.5, 1.0$ Hz, 1H), 7.42–7.40 (m, 2H), 7.28 (dt, $J = 8.0, 1.0$ Hz, 1H), 7.20 (ddd, $J = 9.0, 7.0, 1.0$ Hz, 1H), 7.07 (td, $J = 7.5, 1.0$ Hz, 1H), 4.28–4.18 (m, 2H), 4.17 (d, $J = 17.0$ Hz, 1H), 3.82–3.76 (m, 2H), 3.57 (d, $J = 17.0$ Hz, 1H), 1.20 (t, $J = 7.5$ Hz, 3H), 0.82 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.3, 167.8, 160.2, 140.3, 137.1, 132.7, 130.6, 130.3, 124.9, 123.6, 123.0, 121.8, 119.9, 110.2, 108.6, 67.9, 63.2, 60.8, 36.9, 14.0, 13.7; IR (KBr) ν 3066, 2981, 1736, 1672, 1619, 1600, 1493, 1468, 1367, 1351, 1303, 1240, 1193, 1095, 1026, 944, 860 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_5$ 380.1372; Found 380.1372.

4-(1-(4-Sulfamoylphenyl)-3-(trifluoromethyl)-1*H*-pyrazol-5-yl)benzyl 3-(2',5',12-trioxo-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidin]-1'-yl)propanoate (4q)




83.2 mg (55%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 5:1$ to $1:1$); light yellow solid; mp = 104.5–107.6 $^\circ\text{C}$; ^1H NMR (500 MHz, CDCl_3) δ 7.82–7.78 (m, 3H), 7.62 (ddd, $J = 9.5, 7.0, 1.0$ Hz, 1H), 7.47–7.44 (m, 2H), 7.35–7.30 (m, 5H), 7.23 (d, $J = 8.0$ Hz, 1H), 6.73 (s, 1H), 7.19–7.14 (m, 3H), 7.11 (t, $J = 7.5$ Hz, 1H), 5.49 (s, 2H), 5.09 (s, 2H), 4.02–3.93 (m, 2H), 3.88 (d, $J = 18.5$ Hz, 1H), 3.20 (d, $J = 18.5$ Hz, 1H), 2.78 (td, $J = 6.5, 1.0$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.6, 171.9, 170.5, 160.9, 144.7, 144.1 (q, $J_{\text{C}-\text{F}} = 38.0$ Hz), 142.1, 142.0, 141.6, 137.1 (d, $J_{\text{C}-\text{F}} = 7.2$ Hz), 133.5, 131.2, 130.2, 129.2, 129.1, 128.7, 127.5, 125.5, 124.9, 124.1, 122.8, 122.7, 122.2 (q, $J_{\text{C}-\text{F}} = 267.7$ Hz), 119.2, 110.7, 109.6, 106.7, 106.6, 66.7, 66.1, 40.5, 35.7, 32.1; ^{19}F NMR (376 MHz, CDCl_3) δ -62.3 (s); IR (KBr) ν 3062, 1791, 1716, 1658, 1600, 1494, 1469, 1446, 1346, 1315, 1267, 1234, 1160, 1132, 1097, 973, 842 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M] $^+$ Calcd for $\text{C}_{37}\text{H}_{27}\text{F}_3\text{N}_6\text{O}_7\text{S}$ 756.1614; Found 756.1685.

(8*R*,9*S*,13*S*,14*S*)-13-Methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phenanthren-2-yl 3-(2',5',12-trioxo-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidin]-1'-yl)propanoate (4r)




85.8 mg (68%, dr = 1:1); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to $3:1$); pale yellow solid; mp = 125.0–128.2 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, $J = 7.6$ Hz, 1H), 7.66 (ddd, $J = 9.6, 7.2, 1.2$ Hz, 1H), 7.51 (d, $J = 8.4$ Hz, 1H), 7.48–7.43 (m, 1H), 7.33 (d, $J = 8.0$ Hz, 1H), 7.27–7.22 (m, 3H), 7.06 (td, $J = 8.4, 2.8$ Hz, 1H), 6.84 (dd, $J = 8.4, 2.8$ Hz, 1H), 6.80 (t, $J = 3.2$ Hz, 1H), 4.22–4.15 (m, 1H), 4.12–4.06 (m, 1H), 3.96 (d, $J = 18.4$ Hz, 1H), 3.23 (d, $J = 18.4$ Hz, 1H), 2.99 (t, $J = 6.8$ Hz, 2H), 2.90–2.86 (m, 2H), 2.53–2.47 (m, 1H), 2.42–2.36 (m, 1H), 2.30–2.24 (m, 1H), 2.18–2.07 (m, 1H), 2.05–1.93 (m, 3H), 1.67–1.58 (m, 2H), 1.55–1.37 (m, 4H), 0.90 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.5, 171.9, 169.7, 161.1, 148.4, 142.0, 138.2, 137.7, 137.3, 133.4, 131.0 (two carbons overlap), 130.4, 126.5, 125.1, 124.0, 122.9, 122.6, 121.6, 119.5, 118.8, 110.8, 109.5, 66.7, 50.5, 48.0, 44.3, 40.6, 38.1, 35.9, 35.6, 32.2, 31.7, 29.5, 26.4, 25.8, 21.7, 13.9; IR (KBr) ν 3018, 2933, 1792, 1716, 1668, 1622, 1603, 1491, 1468, 1394, 1371, 1352, 1308, 1250, 1217, 1153, 1088, 1009, 972, 908 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{38}\text{H}_{35}\text{N}_3\text{O}_6$ 629.2526; Found 629.2520.

2-(2-Methyl-5-nitro-1*H*-imidazol-1-yl)ethyl 3-(2',5',12-trioxo-12*H*-spiro[indazolo[1,2-*a*]indazole-10,3'-pyrrolidin]-1'-yl)propanoate (4s)



76.5 mg (72%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 1:1$ to only EtOAc); pale yellow solid; mp = 106.4–108.9 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.94 (s, 1H), 7.86 (dt, $J = 8.0, 1.0$ Hz, 1H), 7.66 (ddd, $J = 9.5, 7.0, 1.0$ Hz, 1H), 7.52–7.47 (m, 2H), 7.34 (d, $J = 8.0$ Hz, 1H), 7.26–7.22 (m, 2H), 7.15 (t, $J = 6.5$ Hz, 1H), 4.57 (td, $J = 5.5, 2.0$ Hz, 2H), 4.45–7.35 (m, 2H), 3.97 (td, $J = 6.5, 1.5$ Hz, 2H), 3.92 (d, $J = 18.5$ Hz, 1H), 3.22 (d, $J = 18.5$ Hz, 1H), 2.75–2.72 (m, 2H), 2.49 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.5, 171.9, 170.2, 161.0, 141.9, 137.3, 133.4, 133.2, 131.2, 130.3, 125.1, 124.1, 122.8, 122.7, 119.5, 110.8, 109.6, 66.6, 63.1, 44.9, 40.6, 35.6, 31.9, 14.4; IR (KBr) ν 3060, 2979, 1716, 1674, 1529, 1488, 1468, 1430, 1363, 1313, 1263, 1187, 1120, 1033, 946, 825 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{26}\text{H}_{22}\text{N}_6\text{O}_7$ 530.1550; Found 530.1548.


1'-(Pyren-1-yl)-12H-spiro[indazolo[1,2-a]indazole-10,3'-pyrrolidine]-2',5',12-trione (4t)



88.2 mg (87%, rotomers ratio = 2:1); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 10:1$ to 5:1); pale yellow solid; mp = 288.3–291.2 °C; ^1H NMR (400 MHz, CDCl_3) **rotomer A:** δ 8.41–8.31 (m, 1H), 8.28–8.21 (m, 3H), 8.19–8.11 (m, 3H), 8.09–8.03 (m, 1H), 8.01 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.70–7.63 (m, 1H), 7.59–7.50 (m, 2H), 7.41 (t, $J = 8.4$ Hz, 1H), 7.28–7.23 (m, 3H), 4.42 (d, $J = 18.8$ Hz, 1H), 3.66 (d, $J = 18.8$ Hz, 1H); **rotomer B:** δ 8.41–8.31 (m, 1H), 8.28–8.21 (m, 3H), 8.19–8.11 (m, 3H), 8.09–8.03 (m, 1H), 7.96 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.79 (d, $J = 9.2$ Hz, 1H), 7.70–7.63 (m, 1H), 7.59–7.50 (m, 2H), 7.32 (td, $J = 7.6, 0.8$ Hz, 1H), 7.28–7.23


(m, 3H), 4.30 (d, J = 18.4 Hz, 1H), 3.59 (d, J = 18.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) **rotomer A**: δ 172.7, 161.7, 142.2, 137.7, 133.7, 132.6, 131.4, 131.1, 131.0, 130.7, 130.0, 129.4, 128.7, 127.4, 126.6, 126.4, 126.1, 125.7, 125.4, 125.3, 125.2, 125.0, 124.6, 124.2, 122.7, 122.5, 122.0, 119.7, 110.9, 110.0, 67.5, 41.4; **rotomer B**: δ 172.0, 160.9, 141.6, 137.2, 133.4, 132.5, 131.3, 131.1, 131.0, 130.5, 130.0, 128.9, 128.3, 127.1, 126.5, 126.3, 126.0, 125.6, 125.4, 125.3, 125.2, 124.9, 124.4, 124.1, 122.6, 122.4, 120.7, 119.6, 110.7, 109.8, 67.1, 41.0; IR (KBr) ν 3496, 3424, 3052, 2925, 2854, 1793, 1720, 1650, 1600, 1510, 1460, 1346, 1307, 1263, 1180, 1118, 946, 844 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{33}\text{H}_{19}\text{N}_3\text{O}_3$ 505.1426; Found 505.1430.

General procedure and ^1H NMR copy for deuterium-labeling experiment



To an oven-dried sealed tube charged with 1-phenyl-1*H*-indazol-3-ol (**1a**) (42.1 mg, 0.2 mmol, 100 mol %), $[\text{RhCp}^*\text{Cl}_2]_2$ (3.1 mg, 0.005 mmol, 2.5 mol %), AgSbF_6 (13.7 mg, 0.04 mmol, 20 mol %), NaOAc (8.2 mg, 0.1 mmol, 50 mol %), and *N*-methylmaleimide (**2a**) (44.4 mg, 0.4 mmol, 200 mol %) was added $\text{CD}_3\text{CO}_2\text{D}$ (10 equiv.) and MeCN (1 mL) under air at room temperature. The reaction mixture was allowed to stir in an oil bath for 3 h at 80 °C. The reaction mixture was cooled to room temperature, diluted with EtOAc (2 mL), and concentrated in vacuo. The residue was purified by flash column chromatography ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 7:1$ to 4:1) to afford **1a** (33.6 mg, 80% recovered yield) and **deuterio-3a** (6.5 mg, 10% yield), respectively.






General procedure and characterization data for the synthesis of rhodacycle-**1a**

To an oven-dried sealed tube charged with 1-phenyl-1*H*-indazol-3-ol (**1a**) (42.1 mg, 0.2 mmol, 100 mol %), [RhCp*Cl₂]₂ (61.8 mg, 0.1 mmol, 50 mol %), and NaOAc (32.8 mg, 0.4 mmol, 200 mol %) was added DCE (3.5 mL) under air atmosphere at room temperature. The reaction mixture was allowed to stir at room temperature for 2 h. The reaction mixture was diluted with EtOAc (5 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (CH₂Cl₂/MeOH = 100:1) to afford 63.2 mg of **rhodacycle-1a** in 48% yield as a dark brown solid, which was further recrystallized by CH₂Cl₂/pentane (1:5) to give **rhodacycle-1a** as a red solid.

Rhodacycle-1a



63.2 mg (48%); eluent (CH₂Cl₂/MeOH = 100:1); red solid; mp = > 300 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 7.82–7.84 (m, 1H), 7.77–7.74 (m, 2H), 7.70–7.67 (m, 2H), 7.58–7.48 (m, 4H), 7.46–7.41 (m, 2H), 7.37 (ddd, *J* = 9.6, 6.9, 1.2 Hz, 1H), 7.28–7.23 (m, 1H), 7.18–7.10 (m, 2H), 6.98 (ddd, *J* = 8.7, 7.2, 0.9 Hz, 1H), 6.89 (td, *J* = 7.5, 1.2 Hz, 1H), 1.72 (s, 15H); ¹³C NMR (100 MHz, CDCl₃) δ 161.9, 153.5, 153.0, 143.6, 138.9, 138.2, 128.9 (two carbons overlap), 128.8, 128.4, 126.7, 126.6, 123.2, 122.4, 121.8, 121.5, 120.6, 119.6, 116.9, 110.2, 110.1, 108.5, 97.1, 97.0, 9.68; HRMS (ion trap, FAB) m/z: [M + H]⁺ Calcd for C₃₆H₃₄N₄O₂Rh 657.1737; Found 657.1731.

Experimental procedure for the reaction of **1a and **2a** using rhodacycle-**1a****

To an oven-dried sealed tube charged with 1-phenyl-1*H*-indazol-3-ol (**1a**) (42.1 mg, 0.2 mmol, 100 mol %), **rhodacycle-1a** (6.6 mg, 0.01 mmol, 5 mol %), NaOAc (8.2 mg, 0.1 mmol, 50 mol %), and *N*-methyl maleimide (**2a**) (44.4 mg, 0.4 mmol, 200 mol %) was added MeCN (1 mL) under air at room temperature. The reaction mixture was allowed to stir in an oil bath for 20 h at 80 °C. The reaction mixture was cooled to room temperature, diluted with EtOAc (2 mL), and concentrated in vacuo. The residue was purified by flash column chromatography (CH₂Cl₂/EtOAc = 7:1 to 4:1) to afford **3a** (45.5 mg) in 71% yield.

Experimental procedure for the reaction of **1a and **2a** using [RhCp*(OAc)₂]**

To an oven-dried sealed tube charged with 1-phenyl-1*H*-indazol-3-ol (**1a**) (42.1 mg, 0.2 mmol, 100 mol %), RhCp*(OAc)₂ (7.2 mg, 0.01 mmol, 5 mol %), NaOAc (8.2 mg, 0.1 mmol, 50 mol %), and *N*-methyl maleimide (**2a**) (44.4 mg, 0.4 mmol, 200 mol %) was added MeCN (1 mL) under air at room temperature. The reaction mixture was allowed to stir in an oil bath for 20 h at 80 °C. The reaction mixture was cooled to room temperature, diluted with EtOAc (2 mL), and concentrated in vacuo. The residue was purified by flash column chromatography (CH₂Cl₂/EtOAc = 7:1 to 4:1) to afford **3a** (36.4 mg) in 57% yield.


General procedure for the spiroannulation of rhodacycle-1a with maleimide for the formation of 3a

To an oven-dried sealed tube charged with **rhodacycle-1a** (32.8 mg, 0.05 mmol, 100 mol %), NaOAc (2.1 mg, 0.025 mmol, 50 mol %), and *N*-methyl maleimide (**2a**) (11.1 mg, 0.1 mmol, 200 mol %) was added MeCN (0.5 mL) under air at room temperature. The reaction mixture was allowed to stir in an oil bath for 20 h at 80 °C. The reaction mixture was cooled to room temperature, diluted with EtOAc (1 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (CH₂Cl₂/EtOAc = 6:1 to 3:1) to afford **3a** (14.4 mg) in 90% yield.

General procedure and characterization data for the reaction of 1-phenyl-1*H*-indazol-3-ol (**1a**) with 1-methyl-1,5-dihydro-2*H*-pyrrol-2-one (**5a**)

To an oven-dried sealed tube charged with 1-phenyl-1*H*-indazol-3-ol (**1a**) (42.1 mg, 0.2 mmol, 100 mol %), $[\text{RhCp}^*\text{Cl}_2]_2$ (3.1 mg, 0.005 mmol, 2.5 mol %), AgSbF_6 (13.7 mg, 0.04 mmol, 20 mol %), NaOAc (8.2 mg, 0.1 mmol, 50 mol %), and 1-methyl-1,5-dihydro-2*H*-pyrrol-2-one (**5a**) (38.8 mg, 0.4 mmol, 200 mol %) was added MeCN (1 mL) under air at room temperature. The reaction mixture was allowed to stir in an oil bath for 20 h at 80 °C. The reaction mixture was cooled to room temperature, diluted with EtOAc (2 mL) and concentrated in vacuo. The residue was purified by flash column chromatography ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 1:1$ to 1:4) to afford **6a** (21.6 mg) in 35% yield.

2-Methyl-2,3,3*a*,14*a*-tetrahydro-1*H*,13*H*-indazolo[1,2-*a*]pyrrolo[3,4-*c*]cinnoline-1,13-dione (**6a**)



21.6 mg (35%); eluent ($\text{CH}_2\text{Cl}_2/\text{EtOAc} = 1:1$ to 1:4); pale yellow sticky solid; ^1H NMR (500 MHz, $\text{CD}_3\text{COCD}_3/\text{CDCl}_3 = 10:1$) δ 7.84 (dt, $J = 8.5, 0.5$ Hz, 1H), 7.79 (dt, $J = 8.0, 1.0$ Hz, 1H), 7.73 (ddd, $J = 8.5, 7.0, 1.5$ Hz, 1H), 7.67 (dt, $J = 8.0, 1.0$ Hz, 1H), 7.58 (ddd, $J = 8.5, 7.5, 0.5$ Hz, 2H), 7.25 (tdd, $J = 15.5, 3.0, 1.0$ Hz, 2H), 3.07 (dt, $J = 16.5, 9.5$ Hz, 1H), 2.92 (ddd, $J = 14.0, 9.5, 2.0$ Hz, 1H), 2.75 (dt, $J = 14.0, 9.5$ Hz, 1H), 2.56 (ddd, $J = 16.5, 9.5, 2.9$ Hz, 1H), 2.38 (s, 3H); ^{13}C NMR (125 MHz, $\text{CD}_3\text{COCD}_3/\text{CDCl}_3 = 10:1$) δ 175.0, 159.9, 142.0, 138.3, 133.9, 132.0, 131.4, 125.5, 125.1, 124.5, 122.9, 120.9, 111.9, 110.3, 85.2, 32.6, 30.8, 25.1; IR (KBr) ν 3469, 2925, 1672, 1584, 1481, 1445, 1380, 1349, 1297, 1245, 1149, 1114, 995, 904 cm^{-1} ; HRMS (quadrupole, EI) m/z: [M]⁺ Calcd for $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_2$ 305.1164; Found 305.1161.

General procedure for the gram scale experiment of **3a**

To an oven-dried sealed tube charged with 1-phenyl-1*H*-indazol-3-ol (**1a**) (1.0 g, 4.8 mmol, 100 mol %), [RhCp^{*}Cl₂]₂ (74.2 mg, 0.12 mmol, 2.5 mol %), AgSbF₆ (329.9 mg, 0.96 mmol, 20 mol %), NaOAc (196.9 mg, 2.4 mmol, 50 mol %), and *N*-methyl maleimide (**2a**) (1.07 g, 9.6 mmol, 200 mol %) was added MeCN (24 mL) under air at room temperature. The reaction mixture was allowed to stir in an oil bath for 20 h at 80 °C. The reaction mixture was cooled to room temperature, diluted with EtOAc (20 mL), and concentrated in vacuo. The residue was purified by flash column chromatography (CH₂Cl₂/EtOAc = 7:1 to 4:1) to afford **3a** (1.38 g) in 90% yield.

X-ray crystallographic data of 1-phenyl-1*H*-indazol-3-ol (**1a**) (CCDC 2096892)

Sample preparation (solvent evaporation)



Compound **1a** (25 mg) was dissolved with 1 mL of CH₂Cl₂ in opened inner vessel, and *n*-pentane (5 mL) as an anti-solvent has been employed in closed outer vessel. After vapor diffusion for 2 days, the single crystals of compound **1a** were obtained.

Detailed experimental description for the crystal measurement of 1-phenyl-1*H*-indazol-3-ol (**1a**)

Crystals grew as colorless plate-like in CH₂Cl₂ by slow evaporation from *n*-pentane. The crystal structures of compound **1a** were determined by standard crystallographic methods. A colorless crystal of C₁₃H₁₀N₂O with approximate dimensions 0.020 x 0.150 x 0.200 mm³ was used for single-crystal X-ray diffraction. The data were collected at 223(2) K using a Bruker D8 Venture equipped with a graphite monochromator with CuK_α radiation ($\lambda = 0.71073 \text{ \AA}$) and a PHOTON III M14 detector in Western Seoul Center of Korea Basic Science Institute. Data collection and integration were performed with SMART APEX3 software package (SAINT).⁴ Absorption correction was performed by multi-scan method implemented in SADABS.⁵ The structure was solved by direct methods and refined by full-matrix least-squares on F² using SHELXTL program package (version 6.14).⁶ All the non-hydrogen atoms were refined anisotropically, and hydrogen atoms were added to their geometrically ideal positions.

Details of crystal data, data collection and structure refinement are listed in Table S2. Further details of the individual structures can be obtained from the Cambridge Crystallographic Data Centre by quoting CCDC 2096892.

ORTEP diagram of 1a (CCDC 2096892)



A colorless plate-like specimen of $\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}$, approximate dimensions 0.020 mm x 0.150 mm x 0.200 mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were measured ($\lambda = 0.71073 \text{ \AA}$).

Table S1: Data collection details for 1a.

| Axis | dx/mm | 2θ/° | ω/° | φ/° | χ/° | Width/° | Frames | Time/s | Wavelength/Å | Voltage/kV | Current/mA | Temperature/K |
|-------|--------|-------|---------|---------|-------|---------|--------|--------|--------------|------------|------------|---------------|
| Phi | 60.663 | 0.00 | 0.00 | 0.00 | 54.74 | 1.00 | 180 | 1.20 | 0.71073 | 50 | 30.0 | n/a |
| Phi | 60.663 | 0.00 | 0.00 | 180.00 | 54.74 | 1.00 | 180 | 1.20 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.663 | 18.54 | -174.46 | -105.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.663 | 18.54 | -174.46 | 102.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.663 | 18.54 | -174.46 | 0.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Phi | 60.663 | 18.54 | 31.54 | 0.00 | 54.74 | 1.00 | 360 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.663 | 18.54 | -174.46 | -156.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Phi | 60.663 | 0.00 | 0.00 | 0.00 | 54.74 | 360.00 | 1 | 108.00 | 0.71073 | 50 | 30.0 | n/a |

A total of 1545 frames were collected. The total exposure time was 3.44 hours. The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The integration of the data using a triclinic unit cell yielded a total of 16137 reflections to a maximum θ angle of 28.42° (0.75 Å resolution), of which 2588 were independent (average redundancy 6.235, completeness = 99.5%, $R_{\text{int}} = 4.00\%$, $R_{\text{sig}} = 3.02\%$) and 2051 (79.25%) were greater than $2\sigma(F^2)$. The final cell constants of $a = 6.772(2) \text{ \AA}$, $b = 9.153(2) \text{ \AA}$, $c = 9.331(2) \text{ \AA}$, $\alpha = 70.250(7)^\circ$, $\beta = 87.119(8)^\circ$, $\gamma = 72.184(8)^\circ$, volume = 517.3(2) Å³, are based upon the refinement of the XYZ-centroids of 5540 reflections above 20 $\sigma(I)$ with $4.646^\circ < 2\theta < 55.07^\circ$. Data were corrected for absorption effects using the Multi-Scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.914. The calculated minimum and maximum transmission coefficients (based on crystal size) are 0.9830 and 0.9980.

The structure was solved and refined using the Bruker SHELXTL Software Package, using the space group P -1, with Z = 2 for the formula unit, $\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}$. The final anisotropic full-matrix least-squares refinement on F^2 with 146 variables converged at $R1 = 4.91\%$, for the observed data and $wR2 = 12.09\%$ for all data. The goodness-of-fit was 1.060. The largest peak in the final difference electron density synthesis was 0.221 e⁻/Å³ and the largest hole was -0.220 e⁻/Å³ with an RMS deviation of 0.037 e⁻/Å³. On the basis of the final model, the calculated density was 1.350 g/cm³ and $F(000)$, 220 e⁻.

Table S2. Sample and crystal data for 1a.

| | | |
|-------------------------------|--|----------------|
| Chemical formula | C ₁₃ H ₁₀ N ₂ O | |
| Formula weight | 210.23 g/mol | |
| Temperature | 296(2) K | |
| Wavelength | 0.71073 Å | |
| Crystal size | 0.020 x 0.150 x 0.200 mm | |
| Crystal habit | colorless plate | |
| Crystal system | triclinic | |
| Space group | P -1 | |
| Unit cell dimensions | a = 6.772(2) Å | α = 70.250(7)° |
| | b = 9.153(2) Å | β = 87.119(8)° |
| | c = 9.331(2) Å | γ = 72.184(8)° |
| Volume | 517.3(2) Å ³ | |
| Z | 2 | |
| Density (calculated) | 1.350 g/cm ³ | |
| Absorption coefficient | 0.088 mm ⁻¹ | |
| F(000) | 220 | |

Table S3. Data collection and structure refinement for 1a.

| | | |
|--|---|---|
| Theta range for data collection | 2.32 to 28.42° | |
| Index ranges | -9≤h≤9, -12≤k≤12, -12≤l≤12 | |
| Reflections collected | 16137 | |
| Independent reflections | 2588 [R(int) = 0.0400] | |
| Coverage of independent reflections | 99.5% | |
| Absorption correction | Multi-Scan | |
| Max. and min. transmission | 0.9980 and 0.9830 | |
| Structure solution technique | direct methods | |
| Structure solution program | SHELXT 2018/2 (Sheldrick, 2018) | |
| Refinement method | Full-matrix least-squares on F^2 | |
| Refinement program | SHELXL-2018/3 (Sheldrick, 2018) | |
| Function minimized | $\Sigma w(F_o^2 - F_c^2)^2$ | |
| Data / restraints / parameters | 2588 / 0 / 146 | |
| Goodness-of-fit on F^2 | 1.060 | |
| Final R indices | 2051 data; I>2σ(I) | R ₁ = 0.0491, wR ₂ = 0.1134 |
| | all data | R ₁ = 0.0640, wR ₂ = 0.1209 |
| Weighting scheme | w=1/[σ ² (F _o ²)+(0.0515P) ² +0.1255P] where P=(F _o ² +2F _c ²)/3 | |
| Largest diff. peak and hole | 0.221 and -0.220 eÅ ⁻³ | |
| R.M.S. deviation from mean | 0.037 eÅ ⁻³ | |

Table S4. Atomic coordinates and equivalent isotropic atomic displacement parameters (\AA^2) for 1a.

$U(\text{eq})$ is defined as one third of the trace of the orthogonalized U_{ij} tensor.

| | x/a | y/b | z/c | U(eq) |
|-----|-------------|-------------|-------------|-----------|
| C1 | 0.2204(2) | 0.02157(16) | 0.61760(15) | 0.0349(3) |
| C2 | 0.3879(2) | 0.06146(16) | 0.66562(16) | 0.0339(3) |
| C3 | 0.5245(2) | 0.99798(18) | 0.79570(17) | 0.0434(4) |
| C4 | 0.6646(2) | 0.0772(2) | 0.80102(19) | 0.0490(4) |
| C5 | 0.6728(2) | 0.2166(2) | 0.6802(2) | 0.0468(4) |
| C6 | 0.5418(2) | 0.28130(18) | 0.55217(18) | 0.0405(3) |
| C7 | 0.3974(2) | 0.20133(16) | 0.54635(15) | 0.0331(3) |
| C8 | 0.1710(2) | 0.38125(16) | 0.30941(15) | 0.0340(3) |
| C9 | 0.9629(2) | 0.47121(19) | 0.29050(18) | 0.0465(4) |
| C10 | 0.8930(3) | 0.6122(2) | 0.1654(2) | 0.0574(5) |
| C11 | 0.0298(3) | 0.6635(2) | 0.06100(19) | 0.0564(5) |
| C12 | 0.2368(3) | 0.5747(2) | 0.08195(18) | 0.0527(4) |
| C13 | 0.3093(2) | 0.43257(18) | 0.20520(17) | 0.0420(3) |
| N1 | 0.13324(17) | 0.12638(14) | 0.48492(13) | 0.0363(3) |
| N2 | 0.24482(17) | 0.23690(14) | 0.43820(13) | 0.0358(3) |
| O1 | 0.16032(17) | 0.89214(13) | 0.69579(12) | 0.0467(3) |

Table S5. Bond lengths (Å) for 1a.

| | | | |
|---------|------------|---------|------------|
| C1-N1 | 1.3136(18) | C1-O1 | 1.3349(16) |
| C1-C2 | 1.427(2) | C2-C7 | 1.4008(19) |
| C2-C3 | 1.405(2) | C3-C4 | 1.371(2) |
| C3-H3 | 0.93 | C4-C5 | 1.402(2) |
| C4-H4 | 0.93 | C5-C6 | 1.368(2) |
| C5-H5 | 0.93 | C6-C7 | 1.401(2) |
| C6-H6 | 0.93 | C7-N2 | 1.3673(18) |
| C8-C13 | 1.383(2) | C8-C9 | 1.383(2) |
| C8-N2 | 1.4222(17) | C9-C10 | 1.384(2) |
| C9-H9 | 0.93 | C10-C11 | 1.376(3) |
| C10-H10 | 0.93 | C11-C12 | 1.373(3) |
| C11-H11 | 0.93 | C12-C13 | 1.382(2) |
| C12-H12 | 0.93 | C13-H13 | 0.93 |
| N1-N2 | 1.3859(16) | O1-H1 | 0.82 |

Table S6. Bond angles (°) for 1a.

| | | | |
|-------------|------------|-------------|------------|
| N1-C1-O1 | 123.56(13) | N1-C1-C2 | 111.87(12) |
| O1-C1-C2 | 124.56(12) | C7-C2-C3 | 120.14(13) |
| C7-C2-C1 | 104.14(12) | C3-C2-C1 | 135.69(13) |
| C4-C3-C2 | 117.90(14) | C4-C3-H3 | 121.1 |
| C2-C3-H3 | 121.1 | C3-C4-C5 | 121.20(14) |
| C3-C4-H4 | 119.4 | C5-C4-H4 | 119.4 |
| C6-C5-C4 | 122.24(14) | C6-C5-H5 | 118.9 |
| C4-C5-H5 | 118.9 | C5-C6-C7 | 116.84(14) |
| C5-C6-H6 | 121.6 | C7-C6-H6 | 121.6 |
| N2-C7-C2 | 107.32(12) | N2-C7-C6 | 130.99(13) |
| C2-C7-C6 | 121.67(13) | C13-C8-C9 | 120.35(14) |
| C13-C8-N2 | 119.58(13) | C9-C8-N2 | 120.05(13) |
| C8-C9-C10 | 119.57(15) | C8-C9-H9 | 120.2 |
| C10-C9-H9 | 120.2 | C11-C10-C9 | 120.31(16) |
| C11-C10-H10 | 119.8 | C9-C10-H10 | 119.8 |
| C12-C11-C10 | 119.72(15) | C12-C11-H11 | 120.1 |
| C10-C11-H11 | 120.1 | C11-C12-C13 | 120.89(16) |
| C11-C12-H12 | 119.6 | C13-C12-H12 | 119.6 |
| C12-C13-C8 | 119.15(15) | C12-C13-H13 | 120.4 |
| C8-C13-H13 | 120.4 | C1-N1-N2 | 106.10(11) |
| C7-N2-N1 | 110.54(11) | C7-N2-C8 | 127.98(12) |
| N1-N2-C8 | 120.27(11) | C1-O1-H1 | 109.5 |

Table S7. Anisotropic atomic displacement parameters (\AA^2) for 1a.

The anisotropic atomic displacement factor exponent takes the form:
 $-2\pi^2 [h^2 a^{*2} U_{11} + \dots + 2 h k a^* b^* U_{12}]$

| | U₁₁ | U₂₂ | U₃₃ | U₂₃ | U₁₃ | U₁₂ |
|-----|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| C1 | 0.0357(7) | 0.0310(7) | 0.0341(7) | -0.0054(6) | 0.0035(5) | -0.0114(5) |
| C2 | 0.0350(7) | 0.0299(6) | 0.0349(7) | -0.0102(5) | 0.0020(5) | -0.0081(5) |
| C3 | 0.0486(8) | 0.0354(8) | 0.0390(8) | -0.0079(6) | -0.0053(6) | -0.0068(6) |
| C4 | 0.0459(8) | 0.0476(9) | 0.0507(9) | -0.0194(8) | -0.0130(7) | -0.0050(7) |
| C5 | 0.0396(8) | 0.0494(9) | 0.0599(10) | -0.0268(8) | -0.0016(7) | -0.0154(7) |
| C6 | 0.0397(7) | 0.0362(7) | 0.0480(8) | -0.0148(6) | 0.0049(6) | -0.0148(6) |
| C7 | 0.0323(6) | 0.0308(7) | 0.0356(7) | -0.0117(5) | 0.0028(5) | -0.0087(5) |
| C8 | 0.0400(7) | 0.0288(6) | 0.0319(7) | -0.0067(5) | 0.0004(5) | -0.0126(6) |
| C9 | 0.0420(8) | 0.0447(9) | 0.0453(8) | -0.0077(7) | 0.0034(6) | -0.0113(7) |
| C10 | 0.0522(10) | 0.0449(9) | 0.0589(11) | -0.0089(8) | -0.0096(8) | 0.0000(8) |
| C11 | 0.0817(13) | 0.0341(8) | 0.0408(9) | -0.0008(7) | -0.0071(8) | -0.0120(8) |
| C12 | 0.0723(11) | 0.0428(9) | 0.0392(8) | -0.0061(7) | 0.0129(8) | -0.0227(8) |
| C13 | 0.0441(8) | 0.0377(8) | 0.0408(8) | -0.0089(6) | 0.0078(6) | -0.0137(6) |
| N1 | 0.0355(6) | 0.0335(6) | 0.0378(6) | -0.0039(5) | 0.0011(5) | -0.0166(5) |
| N2 | 0.0359(6) | 0.0321(6) | 0.0368(6) | -0.0030(5) | -0.0010(5) | -0.0160(5) |
| O1 | 0.0515(6) | 0.0421(6) | 0.0413(6) | 0.0033(5) | -0.0052(5) | -0.0253(5) |

Table S8. Hydrogen atomic coordinates and isotropic atomic displacement parameters (\AA^2) for 1a.

| | x/a | y/b | z/c | U(eq) |
|-----|---------|---------|---------|-------|
| H3 | 0.5200 | -0.0949 | 0.8757 | 0.052 |
| H4 | 0.7559 | 0.0378 | 0.8863 | 0.059 |
| H5 | 0.7706 | 0.2667 | 0.6874 | 0.056 |
| H6 | 0.5482 | 0.3740 | 0.4728 | 0.049 |
| H9 | -0.1296 | 0.4372 | 0.3614 | 0.056 |
| H10 | -0.2470 | 0.6726 | 0.1518 | 0.069 |
| H11 | -0.0176 | 0.7578 | -0.0234 | 0.068 |
| H12 | 0.3294 | 0.6107 | 0.0123 | 0.063 |
| H13 | 0.4494 | 0.3722 | 0.2179 | 0.05 |
| H1 | 0.0676 | -0.1128 | 0.6461 | 0.07 |

X-ray crystallographic data of rhodacycle-1a (CCDC 2095228)

Sample preparation (solvent evaporation)



Isolated **rhodacycle-1a** (50 mg) was dissolved with CH₂Cl₂ (1 mL) and *n*-pentane (5 mL) in a sample vial that has a perforated cap. With slow solvent evaporation for 2 days, the single crystals of **rhodacycle-1a** were obtained.

Detailed experimental description for the crystal measurement of rhodacycle-1a

Crystals grew as red color in CH₂Cl₂ by slow evaporation from *n*-pentane. The crystal structures of **rhodacycle-1a** were determined by standard crystallographic methods. A red block-like crystal of C₃₆H₃₃N₄O₂Rh with approximate dimensions 0.080 x 0.190 x 0.200 mm³ was used for single-crystal X-ray diffraction. The data were collected at 223(2) K using a Bruker D8 Venture equipped with a graphite monochromator with CuK_α radiation ($\lambda = 0.71073 \text{ \AA}$) and a PHOTON III M14 detector in Western Seoul Center of Korea Basic Science Institute. Data collection and integration were performed with SMART APEX3 software package (SAINT).⁵ Absorption correction was performed by multi-scan method implemented in SADABS.⁶ The structure was solved by direct methods and refined by full-matrix least-squares on F² using SHELXTL program package (version 6.14).⁷ All the non-hydrogen atoms were refined anisotropically, and hydrogen atoms were added to their geometrically ideal positions.

Details of crystal data, data collection and structure refinement are listed in Table S10. Further details of the individual structures can be obtained from the Cambridge Crystallographic Data Centre by quoting **CCDC 2095228**.

ORTEP diagram of rhodacycle-1a (CCDC 2095228)



A red block-like specimen of $\text{C}_{36}\text{H}_{33}\text{N}_4\text{O}_2\text{Rh}$, approximate dimensions 0.080 mm x 0.190 mm x 0.200 mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were measured ($\lambda = 0.71073 \text{ \AA}$).

Table S9: Data collection details for rhodacycle-1a (CCDC 2095228).

| Axis | dx/mm | 2θ/° | ω/° | φ/° | χ/° | Width/° | Frames | Time/s | Wavelength/Å | Voltage/kV | Current/mA | Temperature/K |
|-------|--------|-------|---------|---------|-------|---------|--------|--------|--------------|------------|------------|---------------|
| Phi | 60.558 | 0.00 | 0.00 | 0.00 | 54.74 | 1.00 | 180 | 1.20 | 0.71073 | 50 | 30.0 | n/a |
| Phi | 60.558 | 0.00 | 0.00 | 180.00 | 54.74 | 1.00 | 180 | 1.20 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.558 | 18.54 | -174.46 | 153.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.558 | 27.81 | -165.19 | 0.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.558 | 18.54 | -174.46 | -105.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.558 | 18.54 | -174.46 | 102.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.558 | 18.54 | -174.46 | -54.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.558 | 18.54 | -174.46 | 51.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.558 | 18.54 | -174.46 | -156.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Omega | 60.558 | 18.54 | -174.46 | 0.00 | 54.74 | 1.00 | 206 | 10.00 | 0.71073 | 50 | 30.0 | n/a |
| Phi | 60.558 | 0.00 | 0.00 | 0.00 | 54.74 | 360.00 | 1 | 108.00 | 0.71073 | 50 | 30.0 | n/a |

A total of 2009 frames were collected. The total exposure time was 4.73 hours. The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The integration of the data using a monoclinic unit cell yielded a total of 112285 reflections to a maximum θ angle of 25.05° (0.84 Å resolution), of which 5304 were independent (average redundancy 21.170, completeness = 99.9%, $R_{\text{int}} = 4.55\%$, $R_{\text{sig}} = 1.41\%$) and 4740 (89.37%) were greater than $2\sigma(F^2)$. The final cell constants of $a = 12.8432(6) \text{ \AA}$, $b = 14.0502(6) \text{ \AA}$, $c = 16.6156(7) \text{ \AA}$, $\beta = 93.340(2)^\circ$, volume = $2993.2(2) \text{ \AA}^3$, are based upon the refinement of the XYZ-centroids of 9908 reflections above $20 \sigma(I)$ with $5.043^\circ < 2\theta < 56.48^\circ$. Data were corrected for absorption effects using the Multi-Scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.912. The calculated minimum and maximum transmission coefficients (based on crystal size) are 0.8880 and 0.9530.

The structure was solved and refined using the Bruker SHELXTL Software Package, using the space group P 1 21/n 1, with Z = 4 for the formula unit, $\text{C}_{36}\text{H}_{33}\text{N}_4\text{O}_2\text{Rh}$. The final anisotropic full-matrix least-squares refinement on F^2 with 394 variables converged at $R1 = 3.13\%$, for the observed data and $wR2 = 8.68\%$ for all data. The goodness-of-fit was 1.060. The largest peak in the final difference electron density synthesis was 1.850 e⁻/Å³ and the largest hole was -0.604 e⁻/Å³ with an RMS deviation of 0.058 e⁻/Å³. On the basis of the final model, the calculated density was 1.457 g/cm³ and F(000), 1352 e⁻.

Table S10. Sample and crystal data for rhodacycle-1a.

| | | |
|-------------------------------|--|----------------|
| Chemical formula | C ₃₆ H ₃₃ N ₄ O ₂ Rh | |
| Formula weight | 656.57 g/mol | |
| Temperature | 296(2) K | |
| Wavelength | 0.71073 Å | |
| Crystal size | 0.080 x 0.190 x 0.200 mm | |
| Crystal habit | red block | |
| Crystal system | monoclinic | |
| Space group | P 2 ₁ /n | |
| Unit cell dimensions | a = 12.8432(6) Å | α = 90° |
| | b = 14.0502(6) Å | β = 93.340(2)° |
| | c = 16.6156(7) Å | γ = 90° |
| Volume | 2993.2(2) Å ³ | |
| Z | 4 | |
| Density (calculated) | 1.457 g/cm ³ | |
| Absorption coefficient | 0.610 mm ⁻¹ | |
| F(000) | 1352 | |

Table S11. Data collection and structure refinement for rhodacycle-1a.

| | | |
|--|---|---|
| Theta range for data collection | 1.90 to 25.05° | |
| Index ranges | -15≤h≤15, -16≤k≤16, -19≤l≤19 | |
| Reflections collected | 112285 | |
| Independent reflections | 5304 [R(int) = 0.0455] | |
| Coverage of independent reflections | 99.9% | |
| Absorption correction | Multi-Scan | |
| Max. and min. transmission | 0.9530 and 0.8880 | |
| Structure solution technique | direct methods | |
| Structure solution program | SHELXT 2018/2 (Sheldrick, 2018) | |
| Refinement method | Full-matrix least-squares on F^2 | |
| Refinement program | SHELXL-2018/3 (Sheldrick, 2018) | |
| Function minimized | $\Sigma w(F_o^2 - F_c^2)^2$ | |
| Data / restraints / parameters | 5304 / 2 / 394 | |
| Goodness-of-fit on F^2 | 1.060 | |
| Δ/σ_{\max} | 0.001 | |
| Final R indices | 4740 data; I>2σ(I) | R ₁ = 0.0313, wR ₂ = 0.0814 |
| | all data | R ₁ = 0.0369, wR ₂ = 0.0868 |
| Weighting scheme | w=1/[$\sigma^2(F_o^2)+(0.0409P)^2+3.7289P$] where P=(F _o ² +2F _c ²)/3 | |
| Largest diff. peak and hole | 1.850 and -0.604 eÅ ⁻³ | |
| R.M.S. deviation from mean | 0.058 eÅ ⁻³ | |

Table S12. Atomic coordinates and equivalent isotropic atomic displacement parameters (\AA^2) for rhodacycle-1a.

$U(\text{eq})$ is defined as one third of the trace of the orthogonalized U_{ij} tensor.

| | x/a | y/b | z/c | U(eq) |
|-----|-------------|-------------|-------------|------------|
| C1 | 0.8071(2) | 0.7509(2) | 0.26002(11) | 0.0406(6) |
| C2 | 0.9102(2) | 0.7381(2) | 0.29989(18) | 0.0423(6) |
| C3 | 0.0082(3) | 0.7260(2) | 0.2703(2) | 0.0552(8) |
| C4 | 0.0921(3) | 0.7162(3) | 0.3258(3) | 0.0638(9) |
| C5 | 0.0776(3) | 0.7181(3) | 0.4081(2) | 0.0636(10) |
| C6 | 0.9820(3) | 0.7309(2) | 0.4385(2) | 0.0540(8) |
| C7 | 0.8972(2) | 0.7426(2) | 0.38187(18) | 0.0426(7) |
| C8 | 0.7439(2) | 0.7238(2) | 0.46171(17) | 0.0425(7) |
| C9 | 0.7621(3) | 0.7679(3) | 0.53563(19) | 0.0574(9) |
| C10 | 0.7201(3) | 0.7314(4) | 0.6026(2) | 0.0735(12) |
| C11 | 0.6609(4) | 0.6512(4) | 0.5977(3) | 0.0797(14) |
| C12 | 0.6409(3) | 0.6062(3) | 0.5242(3) | 0.0728(11) |
| C13 | 0.6832(3) | 0.6426(2) | 0.4556(2) | 0.0549(8) |
| C14 | 0.54997(18) | 0.6894(2) | 0.16374(15) | 0.0394(6) |
| C15 | 0.4793(2) | 0.6124(2) | 0.15312(19) | 0.0441(7) |
| C16 | 0.4636(3) | 0.5454(2) | 0.0923(2) | 0.0614(9) |
| C17 | 0.3911(3) | 0.4753(3) | 0.1025(3) | 0.0764(12) |
| C18 | 0.3366(3) | 0.4724(3) | 0.1716(3) | 0.0763(12) |
| C19 | 0.3499(3) | 0.5376(3) | 0.2328(3) | 0.0639(10) |
| C20 | 0.4243(2) | 0.6095(2) | 0.2224(2) | 0.0449(7) |
| C21 | 0.4476(2) | 0.7111(2) | 0.35009(18) | 0.0435(7) |
| C22 | 0.3781(3) | 0.6683(3) | 0.4003(2) | 0.0605(9) |
| C23 | 0.3747(3) | 0.6984(3) | 0.4790(2) | 0.0652(10) |
| C24 | 0.4378(3) | 0.7701(3) | 0.5074(2) | 0.0569(9) |
| C25 | 0.5069(2) | 0.8130(2) | 0.45714(18) | 0.0465(7) |
| C26 | 0.5131(2) | 0.7858(2) | 0.37690(17) | 0.0388(6) |
| C27 | 0.5358(2) | 0.9862(2) | 0.31377(18) | 0.0435(7) |
| C28 | 0.5196(2) | 0.9607(2) | 0.23070(18) | 0.0419(6) |
| C29 | 0.6196(2) | 0.9580(2) | 0.19536(17) | 0.0403(6) |
| C30 | 0.6959(2) | 0.9745(2) | 0.25723(18) | 0.0423(7) |
| C31 | 0.6459(2) | 0.98847(19) | 0.33204(17) | 0.0420(7) |
| C32 | 0.4523(3) | 0.0113(3) | 0.3687(2) | 0.0630(9) |
| C33 | 0.4161(3) | 0.9500(3) | 0.1846(2) | 0.0629(9) |

| | x/a | y/b | z/c | U(eq) |
|-----|-------------|-------------|-------------|--------------|
| C34 | 0.6352(3) | 0.9473(3) | 0.10701(19) | 0.0565(8) |
| C35 | 0.8112(3) | 0.9805(3) | 0.2487(2) | 0.0599(9) |
| C36 | 0.7011(3) | 0.0153(3) | 0.4108(2) | 0.0591(9) |
| N1 | 0.73788(18) | 0.76225(17) | 0.31744(13) | 0.0387(5) |
| N2 | 0.79342(19) | 0.76121(18) | 0.39391(14) | 0.0423(6) |
| N3 | 0.53676(18) | 0.73200(16) | 0.23163(14) | 0.0374(5) |
| N4 | 0.45830(19) | 0.68386(18) | 0.27000(15) | 0.0434(6) |
| O1 | 0.78865(16) | 0.75462(17) | 0.18516(10) | 0.0510(5) |
| O2 | 0.62258(16) | 0.71603(16) | 0.11391(11) | 0.0476(5) |
| Rh1 | 0.60155(2) | 0.84694(2) | 0.29261(2) | 0.03282(9) |

Table S13. Bond lengths (Å) for rhodacycle-1a.

| | | | |
|----------|------------|----------|------------|
| C1-O1 | 1.2538(10) | C1-N1 | 1.351(3) |
| C1-C2 | 1.456(4) | C2-C7 | 1.383(4) |
| C2-C3 | 1.388(4) | C3-C4 | 1.384(5) |
| C3-H3 | 0.93 | C4-C5 | 1.391(5) |
| C4-H4 | 0.93 | C5-C6 | 1.366(5) |
| C5-H5 | 0.93 | C6-C7 | 1.407(4) |
| C6-H6 | 0.93 | C7-N2 | 1.384(4) |
| C8-C13 | 1.382(5) | C8-C9 | 1.383(4) |
| C8-N2 | 1.426(4) | C9-C10 | 1.365(5) |
| C9-H9 | 0.93 | C10-C11 | 1.359(6) |
| C10-H10 | 0.93 | C11-C12 | 1.385(6) |
| C11-H11 | 0.93 | C12-C13 | 1.388(5) |
| C12-H12 | 0.93 | C13-H13 | 0.93 |
| C14-N3 | 1.297(3) | C14-O2 | 1.3362(10) |
| C14-C15 | 1.416(4) | C15-C20 | 1.386(5) |
| C15-C16 | 1.387(4) | C16-C17 | 1.372(6) |
| C16-H16 | 0.93 | C17-C18 | 1.380(6) |
| C17-H17 | 0.93 | C18-C19 | 1.371(6) |
| C18-H18 | 0.93 | C19-C20 | 1.408(4) |
| C19-H19 | 0.93 | C20-N4 | 1.367(4) |
| C21-C22 | 1.394(4) | C21-N4 | 1.399(4) |
| C21-C26 | 1.401(4) | C22-C23 | 1.378(5) |
| C22-H22 | 0.93 | C23-C24 | 1.360(5) |
| C23-H23 | 0.93 | C24-C25 | 1.391(5) |
| C24-H24 | 0.93 | C25-C26 | 1.394(4) |
| C25-H25 | 0.93 | C26-Rh1 | 2.043(3) |
| C27-C28 | 1.429(4) | C27-C31 | 1.429(4) |
| C27-C32 | 1.491(4) | C27-Rh1 | 2.168(3) |
| C28-C29 | 1.444(4) | C28-C33 | 1.502(4) |
| C28-Rh1 | 2.143(3) | C29-C30 | 1.398(4) |
| C29-C34 | 1.501(4) | C29-Rh1 | 2.268(3) |
| C30-C31 | 1.445(4) | C30-C35 | 1.498(4) |
| C30-Rh1 | 2.260(3) | C31-C36 | 1.501(4) |
| C31-Rh1 | 2.160(3) | C32-H32A | 0.96 |
| C32-H32B | 0.96 | C32-H32C | 0.96 |
| C33-H33A | 0.96 | C33-H33B | 0.96 |

| | | | |
|----------|----------|----------|----------|
| C33-H33C | 0.96 | C34-H34A | 0.96 |
| C34-H34B | 0.96 | C34-H34C | 0.96 |
| C35-H35A | 0.96 | C35-H35B | 0.96 |
| C35-H35C | 0.96 | C36-H36A | 0.96 |
| C36-H36B | 0.96 | C36-H36C | 0.96 |
| N1-N2 | 1.420(3) | N1-Rh1 | 2.137(2) |
| N3-N4 | 1.398(3) | N3-Rh1 | 2.056(2) |
| O2-H2 | 0.82 | | |

Table S14. Bond angles ($^{\circ}$) for rhodacycle-1a.

| | | | |
|-------------|------------|-------------|----------|
| O1-C1-N1 | 127.0(3) | O1-C1-C2 | 124.8(3) |
| N1-C1-C2 | 108.15(19) | C7-C2-C3 | 121.2(3) |
| C7-C2-C1 | 106.5(2) | C3-C2-C1 | 132.3(3) |
| C4-C3-C2 | 117.6(3) | C4-C3-H3 | 121.2 |
| C2-C3-H3 | 121.2 | C3-C4-C5 | 120.6(3) |
| C3-C4-H4 | 119.7 | C5-C4-H4 | 119.7 |
| C6-C5-C4 | 122.7(3) | C6-C5-H5 | 118.7 |
| C4-C5-H5 | 118.7 | C5-C6-C7 | 116.5(3) |
| C5-C6-H6 | 121.7 | C7-C6-H6 | 121.7 |
| C2-C7-N2 | 108.9(2) | C2-C7-C6 | 121.3(3) |
| N2-C7-C6 | 129.8(3) | C13-C8-C9 | 120.0(3) |
| C13-C8-N2 | 121.5(3) | C9-C8-N2 | 118.4(3) |
| C10-C9-C8 | 120.1(4) | C10-C9-H9 | 120.0 |
| C8-C9-H9 | 120.0 | C11-C10-C9 | 120.6(4) |
| C11-C10-H10 | 119.7 | C9-C10-H10 | 119.7 |
| C10-C11-C12 | 120.4(4) | C10-C11-H11 | 119.8 |
| C12-C11-H11 | 119.8 | C11-C12-C13 | 119.6(4) |
| C11-C12-H12 | 120.2 | C13-C12-H12 | 120.2 |
| C8-C13-C12 | 119.3(4) | C8-C13-H13 | 120.3 |
| C12-C13-H13 | 120.3 | N3-C14-O2 | 122.7(2) |
| N3-C14-C15 | 110.2(2) | O2-C14-C15 | 127.0(3) |
| C20-C15-C16 | 121.7(3) | C20-C15-C14 | 105.8(2) |
| C16-C15-C14 | 132.4(3) | C17-C16-C15 | 117.9(4) |
| C17-C16-H16 | 121.0 | C15-C16-H16 | 121.0 |
| C16-C17-C18 | 120.3(4) | C16-C17-H17 | 119.8 |
| C18-C17-H17 | 119.8 | C19-C18-C17 | 123.4(4) |
| C19-C18-H18 | 118.3 | C17-C18-H18 | 118.3 |
| C18-C19-C20 | 116.3(4) | C18-C19-H19 | 121.8 |
| C20-C19-H19 | 121.8 | N4-C20-C15 | 107.3(3) |
| N4-C20-C19 | 132.3(3) | C15-C20-C19 | 120.4(3) |
| C22-C21-N4 | 123.5(3) | C22-C21-C26 | 121.8(3) |
| N4-C21-C26 | 114.7(3) | C23-C22-C21 | 119.4(3) |
| C23-C22-H22 | 120.3 | C21-C22-H22 | 120.3 |
| C24-C23-C22 | 120.4(3) | C24-C23-H23 | 119.8 |
| C22-C23-H23 | 119.8 | C23-C24-C25 | 120.0(3) |
| C23-C24-H24 | 120.0 | C25-C24-H24 | 120.0 |
| C24-C25-C26 | 122.0(3) | C24-C25-H25 | 119.0 |

| | | | |
|---------------|------------|---------------|------------|
| C26-C25-H25 | 119.0 | C25-C26-C21 | 116.3(3) |
| C25-C26-Rh1 | 127.3(2) | C21-C26-Rh1 | 116.4(2) |
| C28-C27-C31 | 107.3(3) | C28-C27-C32 | 125.5(3) |
| C31-C27-C32 | 127.1(3) | C28-C27-Rh1 | 69.72(16) |
| C31-C27-Rh1 | 70.41(16) | C32-C27-Rh1 | 127.9(2) |
| C27-C28-C29 | 108.4(3) | C27-C28-C33 | 126.3(3) |
| C29-C28-C33 | 124.9(3) | C27-C28-Rh1 | 71.56(16) |
| C29-C28-Rh1 | 75.63(16) | C33-C28-Rh1 | 124.4(2) |
| C30-C29-C28 | 107.4(3) | C30-C29-C34 | 127.5(3) |
| C28-C29-C34 | 125.0(3) | C30-C29-Rh1 | 71.73(16) |
| C28-C29-Rh1 | 66.28(16) | C34-C29-Rh1 | 130.8(2) |
| C29-C30-C31 | 109.1(3) | C29-C30-C35 | 126.5(3) |
| C31-C30-C35 | 124.4(3) | C29-C30-Rh1 | 72.32(16) |
| C31-C30-Rh1 | 67.18(15) | C35-C30-Rh1 | 128.1(2) |
| C27-C31-C30 | 107.3(2) | C27-C31-C36 | 127.0(3) |
| C30-C31-C36 | 125.0(3) | C27-C31-Rh1 | 71.02(16) |
| C30-C31-Rh1 | 74.74(16) | C36-C31-Rh1 | 126.8(2) |
| C27-C32-H32A | 109.5 | C27-C32-H32B | 109.5 |
| H32A-C32-H32B | 109.5 | C27-C32-H32C | 109.5 |
| H32A-C32-H32C | 109.5 | H32B-C32-H32C | 109.5 |
| C28-C33-H33A | 109.5 | C28-C33-H33B | 109.5 |
| H33A-C33-H33B | 109.5 | C28-C33-H33C | 109.5 |
| H33A-C33-H33C | 109.5 | H33B-C33-H33C | 109.5 |
| C29-C34-H34A | 109.5 | C29-C34-H34B | 109.5 |
| H34A-C34-H34B | 109.5 | C29-C34-H34C | 109.5 |
| H34A-C34-H34C | 109.5 | H34B-C34-H34C | 109.5 |
| C30-C35-H35A | 109.5 | C30-C35-H35B | 109.5 |
| H35A-C35-H35B | 109.5 | C30-C35-H35C | 109.5 |
| H35A-C35-H35C | 109.5 | H35B-C35-H35C | 109.5 |
| C31-C36-H36A | 109.5 | C31-C36-H36B | 109.5 |
| H36A-C36-H36B | 109.5 | C31-C36-H36C | 109.5 |
| H36A-C36-H36C | 109.5 | H36B-C36-H36C | 109.5 |
| C1-N1-N2 | 108.3(2) | C1-N1-Rh1 | 119.67(17) |
| N2-N1-Rh1 | 122.78(17) | C7-N2-N1 | 108.1(2) |
| C7-N2-C8 | 121.4(2) | N1-N2-C8 | 119.1(2) |
| C14-N3-N4 | 107.9(2) | C14-N3-Rh1 | 136.18(18) |
| N4-N3-Rh1 | 115.92(17) | C20-N4-N3 | 108.7(2) |
| C20-N4-C21 | 135.6(3) | N3-N4-C21 | 114.5(2) |

| | | | |
|-------------|------------|-------------|------------|
| C14-O2-H2 | 109.5 | C26-Rh1-N3 | 77.44(10) |
| C26-Rh1-N1 | 96.64(10) | N3-Rh1-N1 | 87.78(9) |
| C26-Rh1-C28 | 111.41(11) | N3-Rh1-C28 | 100.12(10) |
| N1-Rh1-C28 | 151.86(11) | C26-Rh1-C31 | 109.05(11) |
| N3-Rh1-C31 | 164.69(10) | N1-Rh1-C31 | 104.80(10) |
| C28-Rh1-C31 | 64.70(11) | C26-Rh1-C27 | 91.76(11) |
| N3-Rh1-C27 | 129.67(10) | N1-Rh1-C27 | 142.54(10) |
| C28-Rh1-C27 | 38.72(11) | C31-Rh1-C27 | 38.58(11) |
| C26-Rh1-C30 | 147.08(11) | N3-Rh1-C30 | 134.61(10) |
| N1-Rh1-C30 | 92.65(10) | C28-Rh1-C30 | 62.60(11) |
| C31-Rh1-C30 | 38.08(11) | C27-Rh1-C30 | 63.02(11) |
| C26-Rh1-C29 | 149.50(11) | N3-Rh1-C29 | 104.15(9) |
| N1-Rh1-C29 | 113.82(10) | C28-Rh1-C29 | 38.09(11) |
| C31-Rh1-C29 | 63.03(10) | C27-Rh1-C29 | 63.36(11) |
| C30-Rh1-C29 | 35.95(10) | | |

Table S15. Anisotropic atomic displacement parameters (\AA^2) for rhodacycle-1a.

The anisotropic atomic displacement factor exponent takes the form: $-2\pi^2 [h^2 a^{*2} U_{11} + \dots + 2 h k a^* b^* U_{12}]$

| | U₁₁ | U₂₂ | U₃₃ | U₂₃ | U₁₃ | U₁₂ |
|-----|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| C1 | 0.0415(15) | 0.0410(15) | 0.0388(15) | -0.0025(12) | -0.0022(12) | -0.0012(12) |
| C2 | 0.0389(15) | 0.0438(16) | 0.0438(16) | -0.0015(13) | -0.0004(12) | 0.0016(12) |
| C3 | 0.0503(19) | 0.058(2) | 0.058(2) | -0.0034(16) | 0.0042(15) | 0.0034(15) |
| C4 | 0.0403(18) | 0.071(2) | 0.080(3) | 0.003(2) | 0.0024(17) | 0.0062(16) |
| C5 | 0.049(2) | 0.068(2) | 0.072(2) | 0.0094(19) | -0.0147(17) | 0.0036(17) |
| C6 | 0.0482(18) | 0.061(2) | 0.0517(19) | 0.0082(15) | -0.0098(15) | 0.0024(15) |
| C7 | 0.0443(16) | 0.0395(15) | 0.0433(16) | 0.0016(12) | -0.0037(13) | -0.0005(13) |
| C8 | 0.0419(16) | 0.0485(17) | 0.0367(15) | 0.0027(12) | -0.0011(12) | 0.0087(13) |
| C9 | 0.057(2) | 0.073(2) | 0.0408(17) | -0.0019(16) | -0.0054(15) | 0.0016(17) |
| C10 | 0.074(3) | 0.105(3) | 0.0407(19) | 0.003(2) | 0.0003(17) | 0.017(2) |
| C11 | 0.078(3) | 0.099(4) | 0.064(3) | 0.036(2) | 0.025(2) | 0.026(3) |
| C12 | 0.072(3) | 0.057(2) | 0.091(3) | 0.023(2) | 0.019(2) | 0.0059(19) |
| C13 | 0.060(2) | 0.0435(18) | 0.062(2) | 0.0020(15) | 0.0080(17) | 0.0047(15) |
| C14 | 0.0414(15) | 0.0362(14) | 0.0397(15) | -0.0051(12) | -0.0054(12) | 0.0034(12) |
| C15 | 0.0435(16) | 0.0334(14) | 0.0534(18) | -0.0057(13) | -0.0132(14) | 0.0048(12) |
| C16 | 0.063(2) | 0.0500(19) | 0.069(2) | -0.0204(17) | -0.0110(18) | -0.0024(17) |
| C17 | 0.079(3) | 0.053(2) | 0.095(3) | -0.030(2) | -0.017(2) | -0.012(2) |
| C18 | 0.064(2) | 0.051(2) | 0.113(4) | -0.013(2) | -0.007(2) | -0.0219(18) |
| C19 | 0.052(2) | 0.050(2) | 0.089(3) | -0.0025(19) | 0.0002(19) | -0.0161(16) |
| C20 | 0.0376(15) | 0.0360(15) | 0.0598(19) | -0.0042(14) | -0.0095(14) | -0.0003(12) |
| C21 | 0.0352(15) | 0.0510(17) | 0.0443(16) | 0.0000(13) | 0.0038(12) | -0.0007(13) |
| C22 | 0.0424(18) | 0.072(2) | 0.067(2) | 0.0089(18) | 0.0064(16) | -0.0131(16) |
| C23 | 0.052(2) | 0.087(3) | 0.059(2) | 0.011(2) | 0.0208(17) | -0.0031(19) |
| C24 | 0.055(2) | 0.074(2) | 0.0435(17) | 0.0034(16) | 0.0147(15) | 0.0126(18) |
| C25 | 0.0496(17) | 0.0517(17) | 0.0386(16) | -0.0046(13) | 0.0065(13) | 0.0061(14) |
| C26 | 0.0356(14) | 0.0419(15) | 0.0392(15) | 0.0007(12) | 0.0046(12) | 0.0046(12) |
| C27 | 0.0514(17) | 0.0338(15) | 0.0454(16) | -0.0063(12) | 0.0023(13) | 0.0027(13) |
| C28 | 0.0453(16) | 0.0345(14) | 0.0449(16) | -0.0014(12) | -0.0056(13) | 0.0015(12) |
| C29 | 0.0496(17) | 0.0320(14) | 0.0389(15) | -0.0006(11) | -0.0003(12) | -0.0052(12) |
| C30 | 0.0475(16) | 0.0317(14) | 0.0473(16) | -0.0001(12) | 0.0004(13) | -0.0086(12) |
| C31 | 0.0548(18) | 0.0303(14) | 0.0404(15) | -0.0060(12) | -0.0021(13) | -0.0065(12) |
| C32 | 0.069(2) | 0.058(2) | 0.064(2) | -0.0117(17) | 0.0160(18) | 0.0154(18) |
| C33 | 0.0501(19) | 0.065(2) | 0.072(2) | -0.0035(18) | -0.0134(17) | 0.0046(17) |
| C34 | 0.077(2) | 0.0533(19) | 0.0396(17) | 0.0035(14) | 0.0044(16) | -0.0077(17) |

| | U₁₁ | U₂₂ | U₃₃ | U₂₃ | U₁₃ | U₁₂ |
|-----|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| C35 | 0.0505(19) | 0.059(2) | 0.070(2) | 0.0015(17) | 0.0024(17) | -0.0167(16) |
| C36 | 0.075(2) | 0.0516(19) | 0.0489(19) | -0.0118(15) | -0.0110(17) | -0.0141(17) |
| N1 | 0.0385(12) | 0.0473(14) | 0.0295(11) | -0.0030(10) | -0.0045(9) | 0.0021(10) |
| N2 | 0.0398(13) | 0.0511(14) | 0.0352(12) | 0.0017(11) | -0.0049(10) | 0.0003(11) |
| N3 | 0.0380(12) | 0.0361(12) | 0.0381(12) | -0.0046(10) | 0.0018(10) | -0.0056(10) |
| N4 | 0.0386(13) | 0.0413(13) | 0.0504(15) | -0.0053(11) | 0.0036(11) | -0.0113(11) |
| O1 | 0.0452(12) | 0.0744(15) | 0.0331(11) | -0.0061(10) | -0.0002(9) | -0.0003(11) |
| O2 | 0.0503(12) | 0.0552(13) | 0.0368(11) | -0.0106(9) | -0.0017(9) | -0.0050(10) |
| Rh1 | 0.03704(14) | 0.03171(13) | 0.02981(13) | -0.00489(8) | 0.00278(9) | -0.00193(8) |

Table S16. Hydrogen atomic coordinates and isotropic atomic displacement parameters (\AA^2) for rhodacycle-1a.

| | x/a | y/b | z/c | U(eq) |
|------|--------|--------|--------|-------|
| H3 | 1.0171 | 0.7245 | 0.2152 | 0.066 |
| H4 | 1.1588 | 0.7083 | 0.3079 | 0.077 |
| H5 | 1.1354 | 0.7103 | 0.4440 | 0.076 |
| H6 | 0.9734 | 0.7318 | 0.4937 | 0.065 |
| H9 | 0.8031 | 0.8224 | 0.5397 | 0.069 |
| H10 | 0.7321 | 0.7616 | 0.6521 | 0.088 |
| H11 | 0.6336 | 0.6264 | 0.6439 | 0.096 |
| H12 | 0.5994 | 0.5520 | 0.5208 | 0.087 |
| H13 | 0.6707 | 0.6127 | 0.4061 | 0.066 |
| H16 | 0.5010 | 0.5479 | 0.0461 | 0.074 |
| H17 | 0.3786 | 0.4296 | 0.0626 | 0.092 |
| H18 | 0.2884 | 0.4238 | 0.1770 | 0.092 |
| H19 | 0.3119 | 0.5344 | 0.2787 | 0.077 |
| H22 | 0.3343 | 0.6197 | 0.3808 | 0.073 |
| H23 | 0.3290 | 0.6696 | 0.5129 | 0.078 |
| H24 | 0.4347 | 0.7905 | 0.5604 | 0.068 |
| H25 | 0.5502 | 0.8613 | 0.4777 | 0.056 |
| H32A | 0.4800 | 1.0090 | 0.4236 | 0.095 |
| H32B | 0.3958 | 0.9669 | 0.3614 | 0.095 |
| H32C | 0.4273 | 1.0744 | 0.3565 | 0.095 |
| H33A | 0.3644 | 0.9303 | 0.2207 | 0.094 |
| H33B | 0.4217 | 0.9030 | 0.1432 | 0.094 |
| H33C | 0.3960 | 1.0098 | 0.1605 | 0.094 |
| H34A | 0.6192 | 1.0063 | 0.0800 | 0.085 |
| H34B | 0.5900 | 0.8982 | 0.0849 | 0.085 |
| H34C | 0.7065 | 0.9304 | 0.0996 | 0.085 |
| H35A | 0.8294 | 0.9442 | 0.2027 | 0.09 |
| H35B | 0.8472 | 0.9553 | 0.2963 | 0.09 |
| H35C | 0.8309 | 1.0457 | 0.2418 | 0.09 |
| H36A | 0.7242 | 1.0802 | 0.4084 | 0.089 |
| H36B | 0.7603 | 0.9744 | 0.4211 | 0.089 |
| H36C | 0.6542 | 1.0086 | 0.4534 | 0.089 |
| H2 | 0.6753 | 0.7330 | 0.1403 | 0.071 |

Computational studies for the stability of tautomers

Experimental details for B3LYP/6-31G* density functional model

Spartan'14 parallel suite (12 threads, 6-core Intel i7-based processor) running on a Windows platform (Wavefunction, Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612, <http://www.wavefun.com>) was used to search possible tautomers and calculate their relative stability. The DFT-B3LYP with 6-31G* basis set was used for estimating the tautomer stability. In the gas phase, the optimized structures of two tautomeric forms were displayed as below and their calculated properties listed in Table S17.






Table S17. Tautomer stability calculation by B3LYP/6-31G* density functional model.



| entry | E HOMO (kJ/mol) | E LUMO (kJ/mol) | Boltzmann Dist | rel. E (kJ/mol) | Dipole |
|-----------------------|--------------------|--------------------|-------------------|-----------------|--------|
| 1a | -519.25 | -76.32 | 0.751 | 0 | 1.02 |
| tautomer of 1a | -538.32 | -101.96 | 0.249 | 2.74 | 4.30 |



References



- (1) (a) K. Gogoi, B. R. Bora, G. Borah, B. Sarma and S. Gogoi, Synthesis of Quaternary Carbon-Centered Indolo[1,2-*a*]quinazolinones and Indazolo[1,2-*a*]indazolones via C–H Functionalization. *Chem. Commun.*, 2021, **57**, 1388–1391; (b) S. Tanimori, Y. Kobayashi, Y. Iesaki, Y. Ozaki and M. Kirihata, Copper-catalyzed synthesis of substituted indazoles from 2-chloroarenes at low catalyst-loading. *Org. Biomol. Chem.*, 2012, **10**, 1381–1387; (c) M. C. Vega, M. Rolón, A. Montero-Torres, C. Fonseca-Berzal, J. A. Escario, A. Gómez-Barrio, J. Gálvez, Y. Marrero-Ponce and V. J. Arán, Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug. *Eur. J. Med. Chem.*, 2012, **58**, 214–227.
- (2) (a) M. A. Walker, The Mitsunobu Reaction: A Novel Method for the Synthesis of Bifunctional Maleimide Linkers. *Tetrahedron Lett.*, 1994, **35**, 665–668; (b) A. Bodtke and H.-H. Otto, Synthesis and Properties of Chiral *N,N*-Maleoyl Derivatives and Diels-Alder Reactions with Cyclopentadiene. *Pharmazie*, 2005, **60**, 803–813; (c) L. Wei, L. Cao and Z. Xi, Highly Potent and Stable Capped siRNAs with Picomolar Activity for RNA Interference. *Angew. Chem., Int. Ed.*, 2013, **52**, 6501–6503; (d) S. Mukherjee and E. J. Corey, Highly Enantioselective Diels-Alder Reactions of Maleimides Catalyzed by Activated Chiral Oxazaborolidines. *Org. Lett.*, 2010, **12**, 632–635.
- (3) J. K. Howard, C. J. T. Hyland, J. Just and J. A. Smith, Controlled oxidation of pyrroles: synthesis of highly functionalized γ -lactams. *Org. Lett.*, 2013, **15**, 1714–1717.
- (4) X.-H. Liu, H. Park, J.-H. Hu, Y. Hu, Q.-L. Zhang, B.-L. Wang, B. Sun, K.-S. Yeung, F.-L. Zhang and J.-Q. Yu, Diverse *ortho*-C(sp²)–H Functionalization of Benzaldehydes Using Transient Directing Groups. *J. Am. Chem. Soc.*, 2017, **139**, 888–896.
- (5) SMART, SAINT and SADABS, Bruker AXS Inc., Madison, Wisconsin, USA, 2016.
- (6) Sheldrick, G. M. SADABS v 2.03, University of Göttingen, Germany, 2002.
- (7) SHELXTL v 6.14; Bruker AXS, Inc: Madison, Wisconsin, USA, 2000.



¹H and ¹³C NMR spectra of all compounds
























































































































































¹⁹F NMR spectra of F-containing compounds



JY-573-19F NMR_376 MHz (CDCl₃)





JY-577-19F NMR_376 MHz (CDCl₃)





JY-576-19 F NMR_376 MHz (CDCl₃)

— 43.732




JY-571-19F NMR_376 MHz (CDCl₃)

— -125.143



JY-601-19F NMR-376 MHz (CDCl₃)



JY-628-19F NMR_376 MHz (CDCl₃)

